

**Curriculum Vitae**  
**KAVITA V. NAIR. Ph.D.**

---

**PRESENT POSITION**

**Professor of Neurology and Pharmacy**  
12850 E. Montview Blvd, Box C-238  
Aurora, CO 80045  
Voice: 303-724-2635  
Fax: 303-724-0979  
Cell: 720-277-5855  
E-Mail: Kavita.Nair@cuanschutz.edu

**EDUCATION**

1999	Ph.D. in Pharmacy Administration (now known as Pharmaceutical Outcomes) University of Michigan, Ann Arbor, MI College of Pharmacy
1994	M.S. in Pharmaceutics University of Toledo, Toledo, OH College of Pharmacy
1991	B. Pharm. in Pharmacy University of Delhi, Delhi, India Hamdard College of Pharmacy

**ACADEMIC APPOINTMENTS AND EXPERIENCE**

2017 – Present	Professor Department of Neurology Rocky Mountain MS Center School of Medicine University of Colorado Anschutz Medical Campus
2013 – Present	Professor Department of Clinical Pharmacy Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus
2007-2013	Associate Professor, Department of Clinical Pharmacy Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus
2009-2014	Director of Graduate Studies (Pharmaceutical Outcomes Program Track) Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus

1999-2006	Assistant Professor, Department of Clinical Pharmacy, Skaggs School of Pharmacy, University of Colorado Anschutz Medical Campus
1994 -1999	Research Fellow, Department of Social and Administrative Sciences College of Pharmacy, University of Michigan, Ann Arbor, MI
1992 - 1994	Graduate Teaching Assistant, Department of Industrial Pharmacy University of Toledo, Toledo, OH
Sept, 1991 - Aug, 1992	Staff Pharmacist Zabeel Pharmacy, Dubai, United Arab Emirates

**PROFESSIONAL SERVICE (University, Statewide and National)**

2020- present	Vice Chair, Coding Payment and Policy Sub-committee, American Academy of Neurology
2019	Member, Industry Relations Task Force, American Academy of Neurology
2017-2020	Member, Coding Payment and Policy Sub-committee, American Academy of Neurology
2019- present	Member, Health Services Research Subcommittee, American Academy of Neurology
2019-present	Member, Board Advisory Group, Connect for Health Colorado
2019-present	Board Member, Liver Health Connection of Colorado
2019-present	Chair, Admissions Committee- Skaggs School of Pharmacy and Pharmaceutical Sciences
2016-2018	Chair, Data Analytics Sub Group- Hepatitis C Stakeholder group, Center for Improving Value in Health Care (CIVHC)
2015-2018	Executive Team, Project ECHO for Hepatitis C in Colorado
2015-2016	Co-Chair, Hepatitis C Disease Burden Group with the Colorado Department of Public Health and Environment
2015-2017	Steering Committee member of the OPT-UP (Optimizing Treatment-Understanding Progression) Initiative in Multiple Sclerosis with Accelerated Cure
2012-2014; 2017- present	Appointed Member, All Payer Claims Database Data Release Review Committee (DRC). The goal of this committee is to consider applications for review and release of APCD data pursuant with legislative rules.
2011-2012	Appointed Member; The Regents of the University of Colorado

	Evaluation Committee. The goal of this committee is to evaluate and select health plan vendors for fiscal year 2013.
2011-2012	Appointed Member; The Regents of the University of Colorado Evaluation Committee for selection of the Data Vendor. The goal of this committee was to evaluate and select data vendors for fiscal year 2013.
2011	Member for the Low-Dose Computerized Tomography (LDCT) Lung Cancer Screening Guideline Development Group. This group developed guidelines on lung cancer screening in conjunction with Health Team Works for Colorado providers
2011-2013	Appointed Member, Health Plan Redesign Panel for a 2 year term to assess proposals from the CU, UCH and UPI community to improve health outcomes in these insured populations
2011-2014	Appointed Member by the Colorado Health Institute as a Member of the Data Advisory Working Group (DAWG) to determine data needs, evaluate projections and develop performance measures for creating the Colorado Health Insurance Exchange (as mandated by the Patient Protection and Affordable Care Act) in 2014
2010-2013	Appointed Member by the Colorado Department of Healthcare Policy and Finance to the All Payer Claims Dataset Advisor Committee (APCD) administered by the • Center for Improving Value in Health Care (CIVHC). The goal of this committee was to create a claims database with medical, pharmacy and enrollment data for 80% of insured individuals in CO.
2010-2013	Chair, All Payer Claims Dataset Subcommittee administered by the Center for Improving Value in Health Care (CIVHC). This committee was responsible for elucidating data fields with payers for inclusion into the dataset
2011-2011	Appointed Member, Evaluation committee for vendor selection for the Colorado APCD committee for data administration.
2011-2012	Alternate Member, University Benefits Advisory Committee (UBAB) from the CU AMC campus. The goal of this advisory committee is to advise the President of CU on developing recommendations for benefit issues that represents the needs of the University community.
2009-2013	Internal consultant (appointment by Chancellor Wilson) for the Health Plan Replacement Project to redesign healthcare benefits for the newly self-insured CU, UPI and UH employee and dependent populations.
2000 - 2002	Faculty representative, Strategic Mission and Planning; Research and Scholarship Group
2001-2002	ACPE Accreditation: University Program Review (Research Programs)

2007-2012 VP of Finance and Governance, Center for Health Value Innovation  
(www.chvi.org)

## TEACHING ACTIVITIES

**Doctor of Pharmacy Curriculum:**  
**School of Pharmacy**  
**University of Colorado Denver**

Spring semester 2013- 2016	<b>Public Health and Health Outcomes 1 (PHRD 6945)</b> <b>Co-Course Coordinator (3 credits)</b> Developed and delivered lectures on the impact of healthcare and drug use policy and reform on pharmacists. Assessed student performance through examinations, active learning and assignments.
Spring semester 1999 - 2012	<b>Pharmacy and Health Care II (PHRD 5450) - Structure and Financing of the US Health Care System</b> <b>Course Coordinator and Primary Instructor (2 credits)</b> Course coordinator for the course. Developed and delivered lectures on the structure and financing of the US health care system. Assessed student performance through examinations and assignments.

**Ph.D. Program in Pharmaceutical Sciences (Pharmaceutical Outcomes Research Track)**  
**Skaggs School of Pharmacy and Pharmaceutical Sciences**  
**University of Colorado**

Fall 2010, 2014	<b>Pharmaceutical and Health Policy (PHSC 7616)</b> <b>Course Coordinator and Primary Instructor (4 credits)</b> Course coordinator for the course. Developed lectures and practicum for PhD students to facilitate research on claims databases
Fall 2010-2011, 2013	PHSC & TXCL 7310: Fundamentals of Pharmaceutical Sciences <b>Lecturer (3 credits)</b>
2008-2018	Special Topics in Pharmaceutical Outcomes Research (PHSC 7570)
Fall, 2012, 2013	<b>Course coordinator (1 credit)</b> Evaluated topics and presentations from students on a weekly basis.
Fall 2015	<b>Theoretical Frameworks used to understand Health Behavior (1 credit under PHSC 7570)</b> To describe seminal frameworks utilized in health services research
Spring 2009	Research Methods in Pharmaceutical Outcomes Research (PHSC 7620) <b>Course Coordinator and Primary Instructor (3 credits)</b>

Course coordinator for the course. Developed lectures about research methods specific to pharmaceutical outcome research. Will help students conduct a database research project.

**Fall 2016 -2018**

**Pharmaceutical Policy (1 credit under PHSC 7570)**

Recurring every fall semester on pharmaceutical policy issues

**Other Teaching**

Fall 2011

Ethics in the Health Professions  
Group facilitator (1 credit)

**Research Teaching**

**Ph.D. Student/Fellowship Advising**

2019- present	Chair, Nick Mendola and Sue Kown PhD students in Pharmaceutical Outcomes Research
2018-2019	Chair for Katia Hannah, PhD student in Pharmaceutical Outcomes Research
2015-2018	Chair David Tabano, Primary Advisor, PhD student in Pharmaceutical Outcomes Research <b>(Graduated)</b>
2012-2014	Chair for Angela Czaja, PhD candidate in Pharmaceutical Outcomes Research <b>(Graduated)</b>
2010-2013	Chair for Robert Brett McQueen and Bill Padulla, PhD candidates in Pharmaceutical Outcomes Research <b>(Graduated)</b>
2008- 20120)	Chair for Julia Slejko, PhD candidate in Pharmaceutical Outcomes Research <b>(Graduated)</b>
2008- 2009	External research advisor for Zach Abbott, DO, Fellow in Spine Rehabilitation Services, Department of Neurology, School of Medicine.

**Research Fellow Advising**

2019-2019	Co-advisor to Jacob Leary, Medical Student, University of Colorado School of Medicine AMC
2013-2015	Co-advisor to Robert McQueen, Post Doctoral Fellow in Pharmaceutical Outcomes Research (PhRMA awardee), Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado AMC
2004-2006	Advisor to Elaine Morrato, Post Doctoral Fellow in Pharmaceutical Outcomes Research, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado AMC

2003-2005 Member, Protocol Committee for William Shrank, MD, VA Research Fellow, University of California at Los Angeles, School of Medicine

**Executive MBA Program in Healthcare at the University of Colorado Denver:**  
**School of Business**

Summer semester 2006-2008 Pharmacoconomics (PBMs and the pricing of pharmaceuticals)

**SERVICE**

School of Pharmacy

2019- present Chair, Admissions Committee  
2014- present Member, Admissions Committee  
2015-2016, 2019 Ad Hoc Member, Appointment, Promotion and Tenure Committee  
2016- present Strategic initiative group 3 (Improve health through research and scholarship)  
2010-2012 Member, Appointment, Promotion and Tenure Committee  
2008-2009 Chair, Appointment, Promotion and Tenure Committee  
2008-2009 Research group for School of Pharmacy Accreditation, SOP, UCD  
2007-present UCD Committee on Research Ethics  
2006- 2008 Faculty representative, Scholastic Academic Appeals Committee  
2003-2005 Faculty representative, Student Ethics and Conduct Committee  
200 -2002 Chair, Research and Scholarship Committee for Strategic Mission of Department of Pharmacy Practice (now known as Department of Clinical Pharmacy)  
2001-2002 Voting Member, Program in Pharmaceutical Outcomes Research

**HONORS**

2014 Leadership Award in Innovation for Multiple Sclerosis, Accelerated Cure, Boston, MA  
2007 ISPOR Best Contributed Paper Award for a Poster Presentation  
2000 Finalist for the Best Paper Award (Economic, Social and Administrative Sciences Section)  
American Pharmaceutical Association  
1998 Blue Cross and Blue Shield Foundation Student Award "Evaluating the effectiveness of formulary systems"  
1994-1999 Charles R. Walgreen Fellow, University of Michigan  
1992-1994 Board of Trustees, Scholarship, University of Toledo  
1991 Graduated with Honors, University of Delhi

**PROFESSIONAL ACTIVITY**

Membership in Professional Organizations

European Committee for the Treatment and Research in Multiple Sclerosis (ECTRIMS)  
American Academy of Neurology (AAN)  
Consortium of Multiple Sclerosis Centers (CMSC)

Academy of Managed Care Pharmacy (AMCP)  
The International Women in Multiple Sclerosis (iWiMS)

### **Professional Society Appointments and Service**

2019- present	Reviewer, Neurology
2019-present	Reviewer, Multiple Sclerosis: Clinical, Experimental, Translational
2018-present	Abstract reviewer, European Committee for Treatment and Research in MS
2017-Present	Editorial Board, Scientific Journal of Multiple Sclerosis
2008-present	Member, Editorial Board for the American Health and Drug Benefits and American Journal of Pharmacy Benefits
2009	Primary Reviewer, Idaho Research Center Grant Program
2009	Reviewer, American Heart Association Grants
2007-present	Peer reviewer, Health Affairs
2006-present	Peer reviewer, JAMA, Health Affairs
2004	Member, Cardiovascular Health Coalition for the State of Colorado

### **SPEAKING ENGAGEMENTS/PRESENTATIONS**

1. **Nair KV (Editor)**, Bedi, G. E/M Coding: The Alphabet Soup. Neurobyte. Scheduled for March 5<sup>th</sup>, 2021. American Academy of Neurology
2. **Nair, KV (Chair)**, McQueen, RB, Kantor, D. The MS Provider's Guide to How Drug's are Priced in the US. 2021 Annual Meeting of the Consortium of Multiple Sclerosis Centers. San Diego June 2-5. June 2; 115-315 pm.
3. **Nair, KV (Chair)**, Johnson, NE. The Neurologist's Guide to Drug Pricing and Lowering Drug Prices for Your Patients on Saturday, 4/17 from 5:00 p.m. – 5:30 p.m., American Academy of Neurology's 73rd Annual Meeting, scheduled for April 17-22, 2021, San Francisco, CA.
4. **Nair, KV.** Making Reimbursement Work In Your Practice. Chapter 3: How to Navigate Prior Authorizations and the Peer Review Process. Practice Management Webinar. June 9. American Academy of Neurology.
5. **Nair, KV.** Making Reimbursement Work In Your Practice. Chapter 4: Understanding Coverage Policies for High-cost Drugs. June 9. American Academy of Neurology.
6. **Nair, KV,** Introduction to Clinical Research: When, Why and How. In The Evolving Research Landscape: Understanding, designing and analyzing studies in multiple sclerosis. May 28<sup>th</sup>, 2-4 pm. 2019 Consortium for Multiple Sclerosis Annual Meeting, Seattle, Washington.
7. **Nair, KV.,** Payers and Progressive Multiple Sclerosis: September 26th, 2019. Genentech Educational Day. University of Colorado Anschutz Medical Campus
8. **Nair, KV.,** Payers and Secondary Progressive Multiple Sclerosis: The Middle Child. March,21, 2019. Novartis Institutional Day. University of Colorado Anschutz Medical Campus.
9. Neurology on the Hill. February 25-26<sup>th</sup>. Washington DC. Met with Representative Jason Crow.
10. **Nair KV.,** Understanding an MS Clinical Trial Research article: Magicians need not apply. September 18<sup>th</sup>, 2018. Webinar for the Rocky Mountain MS Center.
11. **Nair KV (panelist speaker)**, Improving payer relations – The role of specialty pharmacy in neurology practices. November 20<sup>th</sup>,2018. Practice Management Seminar. American Academy of Neurology.
12. **Nair, KV.,** Demystifying observational research for the busy clinician and teacher." Grand Rounds. Department of Physical Medicine and Rehabilitation. University of Colorado Anschutz Medical Campus. June 6<sup>th</sup>, 2018.

13. **Nair, KV.**, Kantor D, Pharmacist Led Strategies to Improve Access to DMTs in MS: The Case of Biosimilars in MS (Glatiramer Acetate). Webinar. April 20<sup>th</sup>, May 3<sup>rd</sup>, May 4<sup>th</sup>, May 24<sup>th</sup>- 2017.
  14. **Nair, KV.**, Pricing and Cost Components in the Estimation of MS Costs. November 14<sup>th</sup>, 2016. Skaggs School of Pharmacy and Pharmaceutical Sciences. Genentech Institutional Day.
  15. **Nair, KV**, Alvarez, EA, Honce, JH. Integrating research metrics as standard of care within a Multiple Sclerosis Academic Medical Center. August 31<sup>st</sup>, 2016. University of Colorado School of Medicine and Department of Neurology. Grand Rounds. August 31<sup>st</sup>, 2016.
  16. **Nair, KV**. The path after pharmacy school for PhDs vs PharmDs. February 16, 2016 Industry Pharmacist Organization (IPHO) with the American Association of Pharmaceutical Scientists (AAPS) Skaggs School of Pharmacy and Pharmaceutical Sciences.
  17. Byers, T; Truesdale, A, Langness, J, Steinfurth, N. **Nair, KV**, Thomas, D. Project ECHO-Hepatitis C and its impact on liver cancer. January 27<sup>th</sup>, 2016. Colorado Senate. Denver, CO
  18. **Nair, KV**. Comparative Effectiveness Research: Challenges and Considerations. November 19<sup>th</sup>, 2015. Skaggs School of Pharmacy and Pharmaceutical Sciences. Genentech Institutional Day.
  19. Campbell, T, **Nair, KV**, Hamilton, K; Self Insured Webinar: Presented by the Center for Improving Value in Healthcare (CIVHC). August 31, 2015.
  20. Birlea, M, **Nair KV.**, Ament, K, Improve access of migraine patients to intravenous treatment in the Outpatient Infusion Clinic. Neurology Grand Rounds. February 26, 2014, Hensel Phelps Auditorium East, University of Colorado Anschutz Medical Campus
- 
21. **Nair, KV.**, Keynote Speaker: Integration of EHR and claims data: Evaluating metabolic syndrome in an academic medical center".LSSkaggs Biomedical Research Symposium. Pre-symposium workshop. September 27<sup>th</sup>, 2012 Aurora, CO.
  22. **Nair KV**, Estes G, Fortner G, Managing Chronic Kidney Disease: An Integrated Approach to Chronic Care Management for Employers. Presentation and workshop at the 2011 IBI/NBCH Health & Productivity Forum: February 28 - March 2, San Francisco, California
  23. **Nair, KV.**, Value in Oncology" Academy of Managed Care Pharmacy's 22nd Annual Meeting & Showcase, April 7-9th, 2010, in San Diego, California.
  24. **Nair, KV.**, "Prescription Copay Reduction Program for Diabetic Employees: Its Impact on Medication costs, Compliance, Healthcare Costs and Utilization for Great West Healthcare" Academy of Managed Care Pharmacy's 20th Annual Meeting & Showcase, April 16-19, 2008, in San Francisco, California.
  25. **Nair, KV.**, Panelist for 3<sup>rd</sup> Annual Executive Forum on Pharmacy Benefit Management for Employers and Health Plans on July 21-22, 2008 in Las Vegas, NV.
  26. **Nair, KV.**, Panelist for the World Congress 3<sup>rd</sup> Annual Employer and Human Capital Congress on January 31, 2008 in Washington, DC.
  27. **Nair, KV.**, "Prescription Copay Reduction Program for Diabetic Employees: Its Impact on Medication costs, Compliance, Healthcare Costs and Utilization for the State of Colorado" for Executive Forum on Value-Based Benefits Design for Employers on May 20, 2008 in Denver, CO.
  28. **Nair, KV.**, "Return on Investment on Value Based Benefit Design" Webinar on June 6, 2008, for the World Research Group.
  29. **Nair, KV.**, "Impact of Anti-depressant Use and Associated Prescription Copays on Health Outcomes" Webinar on March 26, 2008 with Milliman Associates.
  30. **Nair KV**. Pharmacy Benefits and Access Issues. Invited speaker at the Annual Meeting of the Colorado Pharmacists Association Denver, CO, October, 2004.
  31. **Nair KV**. The Value of Pharmaceuticals: Access Issues. Invited speaker at the Denver Cardeo Consumer Health Exposition. Denver, CO, September, 2004.
  32. **Nair KV**. The Tiering Phenomenon in Pharmacy Benefits. Invited speaker at the forum titled "The Value of Medicines". Sponsored by Pfizer Pharmaceuticals, Denver, CO, April, 2004.



33. **Nair, KV.** "Tiering in multi-tiered plans: The evolution of formulary structures". Invited speaker at the 10<sup>th</sup> Annual Meeting of the National Managed Healthcare Congress, March, 2003, Washington DC.
34. **Nair KV.** "Pharmacy Benefit Management: The Value of Multi-tiered Co-payment Systems". Invited speaker at the forum titled "Concerning the Rising Costs of Co-Pays, Unintended Consequences". Sponsored by Pfizer Pharmaceuticals, Denver, CO, August 28, 2002.
35. **Nair KV.** Impact of Multi-Tiered Pharmacy Benefit Plans on Patient Attitudes and Behavior: Preliminary Results. Invited Speaker at Pfizer Pharmaceuticals, Global Headquarters, NY, NY, 2001. **Nair, KV.,**Ganther, J., et al., Evaluating patient attitudes towards multi-tiered pharmacy benefits. Poster presentation at the American Pharmaceutical Association's National Meeting, San Francisco, March, 2001.
36. **Nair, KV.,** Improving the performance of P&T Committees. Podium presentation at the American Pharmaceutical Association's National Meeting, Washington DC, March, 2000.
37. **Nair, KV.,** Ascione., FJA., Improving the Performance of Pharmacy and Therapeutic Committees. Podium presentation at the American Pharmaceutical Association's National Meeting, San Antonio, Texas, March, 1999.
38. **Nair, KV.,** Coombs, JH., Ascione., FJA., Comparative evaluation of medication use policies. Poster presentation at the American Society of Health Systems Pharmacists Midyear Clinical Meeting, Las Vegas, Nevada, December, 1998.
39. **Nair, KV.,** Ascione., FJA., Improving formulary effectiveness. Podium presentation at the Midwest Pharmacy Administration Conference, Columbus, Ohio, August, 1998
40. **Nair, KV.,** Ascione, FJA., Factors influencing performance of Pharmacy and Therapeutics Committees. Podium presentation at the American Pharmaceutical Association's National Meeting, Miami, Florida, March, 1998.
41. **Nair, KV.,** Performance of Pharmacy and Therapeutics Committees. Poster presentation at the Inter-University Committee on Organizational Studies, Ann Arbor, MI, March, 1996.
42. **Nair, KV.,** Kirking., DM. Health professionals attitudes towards the development and use of Drug Utilization Review criteria. Podium presentation at the Midwest Pharmacy Administration Conference, Iowa City, IA. August, 1994.
43. **Nair, KV.,** Siganga,WW. Perceptions of Indian Residents towards Pharmacists and use of Pharmacy Services. Podium presentation at the Ohio Pharmacists Association Annual Meeting, Columbus, Ohio, April, 1994.

#### **GRANT/FUNDING/RESEARCH ACTIVITY**

**Note:** For all studies wherein I am listed as the Principal Investigator (PI) or Co-Principal Investigator (Co-PI) my role in the study included primary responsibility for the following activities (as appropriate): identification of funding source, development and writing of the research proposal, identification of collaborators, preparation and submission of the grant proposal, coordination of all activities pertaining to the study, documentation and maintenance of all records pertaining to the study, obtaining approval from the Colorado Multiple Institutional Review Board, data collection preparation and submission of abstracts and manuscripts resulting from the study. For all studies where I am listed as the co-investigator, my responsibilities included a secondary role in the activities listed above.

#### **Novartis**

##### *Combining Metformin and the B Cell Depleting Therapy Ofatumumab in the Treatment of Relapsing Forms of Multiple Sclerosis: A Preliminary Exploration*

The aim of this study is to conduct a preliminary randomized, placebo controlled, blood biomarker study of metformin as add on therapy in patients initiating therapy with ofatumumab for relapsing or progressive forms of MS.

Funding period: TBD

Role: *Co-Principal Investigator* (35% effort) \$1.5M

Status: Pending

### **Genentech**

*Evaluating the Feasibility of Pandemic Forward, Telehealth Based Home Based Infusions for Ocrelizumab Users: Measuring Patient Experiences and Safety Outcomes*

The aim of this study is to develop and investigate the feasibility, safety and patient experience of a home infusion model partnering with an outside specialty infusion services for ocrelizumab patients using the two-hour infusion protocol monitored by telehealth visits for translation into real world clinical practice

Funding period: January 15-December 30, 2021

Role: *Co-Principal Investigator* (25% effort), \$1,000, 855.

Status: Funded

### **PhRMA Foundation**

“Center of Excellence for Pharmaceutical Value (pValue)” Pharmaceutical Value (pValue)

Aims to apply and test novel methods for value assessment that encourage stakeholder engagement and promote value-based decision making. pValue is a recipient of the PhRMA Foundation’s Value Assessment Initiative Centers of Excellence Award.

Funding period: Jan 1, 2019- Dec 31, 2021

Role: *Co- I* (10% effort) \$450,000

Status: Funded

### **Bristol Meyers Squibb**

*Establishing Normative Values for Biomarkers in Multiple Sclerosis using Healthy Controls vs.*

The objective of this study is to create a biorepository of serum samples of healthy controls and people with MS through a collaboration between The University of Colorado Anschutz Medical Campus and Washington University in St. Louis.

Funding period: TBD (due to the pandemic)

Role: *Co- PI* (20% effort) \$387,000

Status: Funded

### **American Academy of Neurology**

*Part D Cost Variation: The Role of Cost Trajectories from 2013-2017 for the Most Common Neurologic Brand-Name and Generic Drugs*

This study will use Medicare Part D dataset from 2013-2017 to examine the cost trajectory for the most common neurologist-prescribed brand-name and generic drugs in the Medicare Part D population.

Funding period: Oct 1, 2019- May 1, 2020

Role: *Co- PI* (10% effort), \$26,000

Status: Funded

### **Department of Neurology, University of Colorado School of Medicine**

*Rocky Mountain Neuroimmunology Translational Core*

Development of a translational core laboratory for the SIMOA bead assay platform technology for evaluating biomarkers that measure disease progression and response to treatment in neurological conditions.

Funding period: March 1, 2019- March 31, 2020

Role: *Co- Director* (25% effort), \$2,000,000

Status: Funded

**Genentech**

*An open label study to evaluate safety and tolerability of shorter infusion of ocrelizumab in patients with primary progressive and relapsing multiple sclerosis.*

The objective of this study is to compare the impact of a shorter infusion protocol for patients taking ocrelizumab on safety and tolerability related outcomes

Funding period: August 17, 2018- July 31<sup>th</sup>, 2019

Role: *Co-Principal Investigator* (5% effort), \$497,032

Status: Funded

**Biogen**

*Characterizing GI events in early versus recent TECFIDERA cohorts at two large MS centers: a retrospective chart review study*

The primary objective of the study is to compare discontinuation rate due to GI symptoms in the first year after initiating TECFIDERA between an early (immediate post launch) and recent TECFIDERA cohort of MS patients at two MS centers.

Funding period: September 1, 2018-September 1, 2019.

Role: *Co-Principal Investigator* (25% effort), \$202,945

Status: Funded

**NIH Exploratory/Developmental Research Grant Program (Parent R21)**

*Disparities in Access to Specialty Drugs in Colorado*

This proposed R21 seeks to test the feasibility of using a state-level All Payer Claims Database to answer key questions related to disparities in access and patient response to specialty drug coverage in the health insurance for patients diagnosed with one of five conditions that commonly include specialty drugs in treatment regimens (HIV/AIDS, RA, MS, cancer, and hepatitis C).

Funding period: January, 2019- June, 30, 2022

Role: *Co- Investigator* (5% effort), \$474,532

Status: Pending

**Patient Centered Outcomes Research Institute (PCORI)**

*Second Generation DMTs Comparative Effectiveness Pragmatic Trial Evaluating RRMS (SCEPTER)*

The primary goal of this study is to examine the comparative effectiveness, safety, and tolerability of the three key Second Generation DMTs that include dimethyl fumarate, fingolimod or ocrelizumab/rituximab

Funding period: 36-60 months

Role: *Co- Investigator* (25% effort), \$14,254,276

Status: Not funded

**Genentech**

*Evaluating the Tolerability and Safety Profile of Switching from Rituximab to Ocrelizumab: A Real World Evaluation of Patients with Relapsing and Progressive Forms of Multiple Sclerosis*

The objective of this study is to compare the impact of switching from Rituximab to Ocrelizumab on infusion related reactions and immunogenicity profile

Funding period: June 1, 2017- May 30<sup>th</sup>, 2019

Role: *Co-Principal Investigator* (15% effort), \$1,359,714.42

Status: Funded

**Novartis**

*Comparison of First vs. Second Line Use of Gilenya on Real World Clinical Efficacy and MRI Based Outcomes: A Two-Site Retrospective Study*

The objective of this study is to compare first vs second line Gilenya on clinical and MRI efficacy measures

Funding period: January, 2016-January, 2017

Role: Principal Investigator (10% effort), \$198,749

Status: Funded

**Gilead Sciences**

*The Estimated Cost of an SVR in Liver Transplant Recipients: Comparison of All Oral Treatment Combinations*

The objective of this study is to compare the cost of SVR for all oral treatments in transplant patients

Funding period: May 1, 2016- September 30th, 2017

Role: Co-Principal Investigator (20% effort), \$438,922 (Sub contract amount \$181,112)

Status: Funded

**Colorado Health Foundation**

ECHO Colorado (Extension for Community Health Outcomes in Colorado, based at the University of Colorado Anschutz Medical Campus, ECHO Colorado builds learning communities connected by video-conferencing technology across the rural and underserved areas in the areas of Hepatitis C among others.

Funding period: May 2016- December 2019

Role: Co- Investigator (15% effort), \$3.3 million

Status: Funded

**Novartis**

*The Impact of Transition times on Switching from Tysabri to Gilenya on Imaging and Clinical Effectiveness Outcomes*

The objective of this study is to compare transition times (washout times) between switching from Tysabri

Funding period: Feb 2015-December, 2015

Role: Co Investigator (10% effort), \$110,207

Status: Funded

**Novartis**

*Comparative Effectiveness of Long Term Gilenya (Fingolimod) versus Copaxone (Glatiramer acetate) On Brain Atrophy Rates, Cognition and Patient Reported Outcomes in Patients with Multiple Sclerosis (MS)*

The objective of this study is to compare long term gilenya and copaxone users on three sets of triangulated measures

Funding period: June 2014-June 2018 (Cost Amendment in 2015)

Role: Principal Investigator (5% effort), \$725,416

Status: Funded

**Biogen Idec**

*Examining the Comparative Effectiveness of Natalizumab versus Fingolimod on Patient Reported Outcomes in Patients with Multiple Sclerosis*

The objective of this study is to compare patient reported outcomes between new starts of natalizumab and fingolimod users

Funding period: October 2013-April 2018

Role: Principal Investigator (15% effort), \$449,758

Status: Funded

**Biogen Idec**

*Does Long Term Natalizumab Therapy Normalize Brain Atrophy Rates and QOL in RRMS? A Longitudinal Study Using Whole Brain, Neocortical and Subcortical, Atrophy Rates and Patient Reported Outcomes)*

The objective of our study is to examine the long term impact of natalizumab therapy on MRI volumetric and PROs.

Funding period: November 2013-August, 2018

Role: Co-Principal Investigator (6% effort), \$753,175

Status: Funded

### **Astra Zeneca**

*Economic Burden of Cardiometabolic Risk Factor Clusters in the United States*

The objective of this study was to the incremental impact of cardiometabolic risk factors on expenditures and productivity for the MEPS database

Funding period: January 1, 2015 - December 31st, 2015

Role: Principal Investigator (15% effort), \$135,036

Status: Funded

### **Astra Zeneca**

*Exploring assessment of renal function, patient characteristics, and changes with progression of chronic kidney disease among a real world population with type 2 diabetes*

The objective of this study was to examine the assessment of renal impairment in type 2 diabetic patients using EMR and claims data on healthcare utilization and expenditures

Funding period: January 1, 2015- December 31<sup>st</sup>, 2015

Role: Principal Investigator (10% effort), \$165,500

Status: Funded

### **Gilead Sciences**

*Comparative Effectiveness of Ranolazine Versus Traditional Therapies in Chronic Stable Angina and Diabetes Mellitus: Impact on Cardiac Interventions, Healthcare Resource Utilization and Expenditures*

The objective of our study is to examine the comparative effect of ranolazine vs traditional anti-anginal therapies on cardiovascular outcomes

Funding period: November 2013-November, 2014

Role: Principal Investigator (25% effort), \$212,630

Status: Funded

### **Patient Centered Outcomes Research Institute (award number AD-1304-6451)**

*Improving Health Outcomes among Native Americans with Diabetes and Cardiovascular Disease*

The goal of this project is to describe the health status, service use, and treatment costs for American Indians and Alaskan Indians with diabetes

Funding period: 10/1/13-9/30/16

Role: Co-Investigator (10%), \$1,994,796

Status: Funded

### **Daiichi Sankyo**

*Assessment of Blood Pressure Control in Patients at Goal on Olmesartan Monotherapy After Switching to either Irbesartan, Losartan or Valsartan*

The objective of our study is to assess maintenance of BP control in patients at recommended BP goal values on olmesartan monotherapy after switching to irbesartan, losartan or valsartan.

Funding period: 2-1-13 to 2-1-2014

Role: Principal Investigator (15% effort), \$77,337  
Status: Funded

#### **Takeda**

*Characterizing Comparative Effectiveness of Hydrochlorothiazide with Chlorthalidone Using Two Ratios of Potency in a Real World Managed Care Population*

To compare the real world effectiveness of chlorthalidone versus hydrochlorothiazide in a managed care population.

Funding period: 1-1-13 to 02-28-2014

Role: Principal Investigator (15% effort), \$120,731

Status: Funded

#### **Janssen**

*Estimating the Burden of Illness for Employees and their Dependents with Acute Coronary Syndrome (ACS) A Retrospective Population Health Management Approach*

To determine the economic burden associated with acute coronary syndrome

Funding period: 04-11-12 to 04-10-15

Role: Principal Investigator (20% effort), \$185,873

Status: Funded

#### **Medicaid: Drug Utilization Review**

Funding period: 6-1-2012 to 12-30-2014

Role: Co Investigator (10% effort), \$351,000

Status: Funded

#### **University of Colorado Health and Welfare Trust**

Proposal for Evaluating Year one of Self Insured Status

Evaluating the impact of self-insured funding status after year one on employees and dependents of the Trust

Funding period: 1-1- 2013 to 6-30-2013

Role: Principal Investigator (30% effort), \$300,000 (taken over from Dr. Ross in 2/2012 due to his departure from the University)

Status: Funded

#### **University of Colorado Health and Welfare Trust Providing Medication Therapy Management Services to Employees and Dependents of the Trust**

Evaluating, assessing and implementing changes in medication use needs for employees and dependents of the Trust

Funding period: 2-1-2012 to 2-1-2014

Role: Co-Principal Investigator (10% effort), \$225,543

Status: Funded

#### **Amgen**

Examining the impact of different drug delivery systems for osteoporosis medications on fracture rates and expenditures

To determine the impact of differential copay levels for hypertensive medications on various outcomes.

Funding period: 9-1-10 to 6-30-13

Role: Principal Investigator (25% effort), \$208,018

Status: Funded

### **Skaggs Scholars Program**

Medication regimen complexity methods and measurement in defined clinical populations  
To implement and validate a medication complexity tool (MRCI) on diverse populations (hypertensives, diabetics, seniors and HIV patients)  
Funding period: 07-1-2011 to 6-30-2013  
Role: *Co-Investigator* (3% effort), \$188,000  
Status: Funded

### **2010-2012**

**Agency for Healthcare Research and Quality (AHRQ) Request for Task Order (RFTO) through the ACTION program (Accelerating Change and Transformation in Organizations and Networks) June 2010. Sub-contract was awarded to The Centers for American Indian and Alaska Native Health (CAIANH) at the Colorado School of Public Health.**

Comparative Effectiveness of Health Care Delivery Systems for  
American Indian and Alaska Natives Using Enhanced Data Infrastructure  
To determine the pharmacy utilization patterns for 14 American Indian and Alaska Native sites  
Funding Period: June 15- September 30, 2012  
Role: *Co-Investigator* (15%) \$30,743  
Status: Funded

### **Novartis**

*Analysis of Healthcare Costs Associated with Acute Gout Flares*  
To determine costs associated with various levels of severity of gout flares  
Funding period: 1-20-11 to 12-30-11  
Role: *Principal Investigator* (12% effort), \$79,422  
Status: Funded

### **Centocor Ortho Biotech**

*Evaluating the impact of a disease management program in chronic kidney disease on health outcomes*  
To identify the impact of identifying diabetic and hypertensive patients at risk for chronic kidney disease and referring them to nephrologists for early intervention and better health outcomes  
Funding period: 12-22-2009 to 12-31-11  
Role: *Principal Investigator* (30% effort), \$128,611  
Status: *Funded*

### **University of Colorado Trust**

*Creating a Customized Formulary for the University of Colorado Trust Health Plans*  
To evaluate the current formulary for UA Net patient and dependents  
Funding period: 2011-2012  
Role: *Principal Investigator* (5% effort), \$51,538  
Status: *Funded (in contracting)*

### **Pinnacol Assurance**

*Research Council Examining Issues related to Workmen's Compensation and Health*  
Evaluating, assessing and implementing changes in medication use needs for employees and dependents of the Trust  
Funding period: 3-1-11 to 3-1-12

Role: Co-Investigator (5% effort), \$177,910  
Status: *Funded (in contracting)*

#### **Centocor Ortho Biotech**

*Evaluating the impact of a disease management program in chronic kidney disease on direct and indirect costs for employees in the Healthcare 21 Coalition*

To identify the impact of identifying diabetic and hypertensive patients at risk for chronic kidney disease and intervening early on direct and indirect costs.

Funding period: 12-22-2009 to 12-31-2011

Role: Principal Investigator (30% effort), \$99,567

Status: *Funded*

#### **Colorado Department of health Care Policy and Financing**

*Expansion of Diabetes Self-Management Training Infrastructure to Pharmacies in Rural and Underserved Colorado*

To evaluate barriers associated with diabetes self-management among rural communities

Funding period: 12-01-2009 to 3-28-2012

Role: Co-Investigator (2% effort) \$57,253

Status: *Funded*

#### **Daiichi- Sankyo**

*Evaluating the Impact of a Prescription Copay Levels for Anti Hypertensive Medications on Medication and Healthcare Utilization, Medication Adherence and Expenditures*

To determine the impact of differential copay levels for hypertensive medications on various outcomes.

Funding period: 1-11-2010 to 11-12-2010

Role: Principal Investigator (20% effort), \$95,098

Status: *Funded*

#### **Novartis**

*Evaluating the burden of illness for osteoporosis and COPD.*

To determine total direct and indirect costs for patients with osteoporosis and COPD compared to those who do not have the disease.

Funding period: 7-31-2009 to 7-30-2010

Role: Principal Investigator (10% effort), \$78,523

Status: *Funded*

#### **Novartis**

*Comparing pre and post gap Medicare beneficiaries in a MAPD plan for members with osteoporosis, COPD, diabetes, CHF*

To determine how the coverage gap impacts medical and pharmacy utilization for MAPD members with select chronic diseases.

Funding period: 2-01-2010 to 1-31-2011

Role: Principal Investigator (20% effort), \$46,471

Status: *Funded*

#### **2008-2009**

#### **Colorado Clinical Guidelines Collaborative-Patient Centered Medical Home (PCMH) Project**

*Developing and Evaluating Pay for Performance (P4P) Measures for PCMHs*



The Colorado Clinical Guidelines Collaborative (CCGC) will serve as the Convening Organization and provide technical assistance for the PCMH Pilot practices in Colorado. The P4P portion of pilot will be evaluated by Dr. Kavita. V. Nair to determine the effect on cost trends. Funding is provided by The Colorado Trust and The Commonwealth Fund.

Funding period: June 1, 2007 – October 31, 2012

Role: Investigator (10% effort; no salary offset)

Status: *Funded*

### **Ethicon**

*Evaluating the impact of mesh type for hernia repair on various outcomes.*

To determine whether the type of mesh and whether it was placed or not affects medical and complication rates for patients undergoing hernia repair.

Funding period: 8-25-2009 to 8-24-2010

Role: Principal Investigator (35% effort), \$73,289

Status: *Funded*

### **Pfizer**

*Evaluation of patient outcomes for NCQA, HSRP and Patient Centered Medical Home certified Physicians (PCMH) compared to non NCQA, HSRP and PCMH physicians*

To compare patients treated under certified medical homes to those not treated in certified medical homes on various outcomes.

Funding period: 4-1-2009 to 7-31-2011

Role: Consultant (5% effort) \$7,182

Status: *Funded*

### **Novartis**

*Evaluating Patterns of Monitoring for Multiple Sclerosis, Safety of Drug Therapy and Co-morbidities and Associated Costs Through a Retrospective Database Analysis*

To determine which tests and procedures, their frequency and associated expenditures are used for monitoring MS, drug therapy for MS and symptom management in newly diagnosed and existing MS patients.

Funding period: 10-1-2008 to 9-30-2009

Role: Principal Investigator (34% effort), \$103,480

Status: *funded*

### **Novartis**

*Improving Adherence in the Hypertensive Population Using a Barrier Assessment and Intervention Model for the Commercially Insured and Medicare population.*

To examine individual specific barriers to hypertension and to design interventions to address these barriers for a commercial and Medicare population.

Funding period: 4-1-2008 to 3-31-2010

Role: Principal Investigator (40% effort), \$208,058

Status: *funded*

### **Medicare Payment Advisory Commission (MedPAC)**

*Task Order (RFP 03-06-1MedPAC) for Medicare Related Projects*

*Award Number 6839*

Contract status for this project was awarded to the Division of Healthcare Policy and Research at the University of Colorado at Denver and the Health Sciences Center. The purpose of this contract will be to

respond to specific task orders issued by MedPAC on topics related to the Medicare population. The specific award has is to examine the impact of the Medicare Part D Pharmacy Benefit on utilization and expenditures

Role: Principal- Investigator

Funding period: 7-2-2007 to 6-30-2008

Status: *Funded*

**Project Title:** Impact of Medicare Part D on pharmacy and medical services, clinical outcomes and spending for a Medicare Advantage population

**Role:** Principal Investigator (17% effort), \$130,754

Status: *funded*

### **Agency for Healthcare Research and Quality (AHRQ)**

*Developing Evidence to Inform Decisions about Effectiveness: The DEcIDE Network*

Contract status for this project was awarded to the School of Medicine and the School of Pharmacy. The purpose of this contract will be to create a collaborative research and practice-based network program that will assist AHRQ and other Federal Agencies with implementation of Section 1013 of the Medicare Modernization Act of 2003 (MMA).

Role: Co- Investigator, (effort and funding amount to be determined based on specific issued task orders)

Funding period: September, 05- September, 06

Status: *Funded*

### **Pfizer**

*Impact of the Medicare Part D Pharmacy Benefit Design on Pharmacy and Medical Utilization for Select Chronic Conditions*

To conduct a pre-post analysis of individuals who switched from a Medicare Choice Plan in 2005 to a MA-PD in 2006 on utilization and expenditures

Role: Principal- Investigator (34% effort), \$86,362,

Funding period: 8-30-2007 to 2-28-2009

Status: *Funded*

### **Novartis**

*Impact of the Medicare Part D Pharmacy Benefit Design on the Pre Gap, Gap and Post Gap Pharmacy Utilization and Expenditures for Individuals with Hypertension*

To examine the differences in pharmacy utilization and expenditures for individuals with hypertension in the pre gap, gap and post gap phases of the Medicare Part D benefit.

Role: Principal- Investigator (33% effort), \$73,680

Funding period: 9-1-2007 to 7-31-2010

Status: *Funded*

### **Astra Zeneca**

*Survey of Community Pharmacist's Management of Dyspeptic and Reflux Symptoms*

Using a national sample of community pharmacists, the overall goal of the study is to evaluate Pharmacist recommendations for the OTC management of dyspeptic and reflux symptoms.

Role: Co- Investigator (10% effort), \$57,187

Funding period: July 06-July 07

Status: *Funded*

### **Amgen**

*Comparing Medication Utilization, Medical Service Resource Utilization and Healthcare Expenditures for Etanercept, Infliximab and Adalimumab: A Six Year Longitudinal Analyses*

The goal of this project is to the overall objective of the study is to examine the impact of etanercept, infliximab and adalimumab on medication utilization patterns, medical service utilization and overall healthcare expenditures.

Role: *Principal Investigator* (30% effort), \$101,697

Funding period: 12-21-2005 to 1-31-2007

Status: *Funded*

**GlaxoSmithKline**

*The Impact of Consumer Driven Health Plans offered by Schneider Corporation On Pharmacy Utilization,, Medical Utilization and Healthcare Expenditures for Chronic Disease Sufferers: Pre-Post Analysis*

The goal of this project is to examine the effect of CDHPs on pharmaceutical and medical utilization and overall healthcare expenditures for selected chronic disease sufferers and compare these patterns of care to those observed when members were enrolled in a three-tier pharmacy benefit plan.

Role: *Principal Investigator* (20% effort), \$94,671

Funding period: 8-1-2005 to 6-30 2009

Status: *Funded*

**GlaxoSmithKline**

*Evaluating the Impact of Reducing Prescription Copays for Diabetic Medications on Clinical Targets, Medication and Healthcare Utilization and Expenditures in a Diabetes Disease Management Program Behavior and Medical Service Utilization and Total Healthcare Expenditures for Diabetics*

The goal of this project is to examine is to examine the impact of reducing prescription copays for diabetic medications on pharmacy utilization and costs

Role: *Principal Investigator* (35% effort till Dec 06, 15% from Jan-Dec 07), \$170,953

Funding period: 10-1-2005 to 6-30-2010

Status: *Funded*

**Eli Lilly**

*The Impact of Pharmacy Benefit Coverage for Duloxetine on Pharmacy and Medical Utilization and Healthcare Expenditures*

The goal of this project is to examine the *tier placement of duloxetine* in one, two and three-tier plans and the *associated prescription copays* on medication adherence and pharmacy expenditures. In addition, the tier placement of duloxetine will be compared to that of escitalopram and venlafaxine on similar outcomes. In addition, the overall impact of pharmacy benefit coverage for duloxetine on medical service utilization and overall healthcare expenditures will also be examined.

Role: *Principal Investigator*, (35% effort), \$145,779

Funding period: 6-15-2005 to 7-1-2007.

Status: *Funded*

**Pfizer Pharmaceuticals**

*Comparing Consumer Driven Health Plan with Three-Tier Pharmacy Benefit Plans: Their Impact On the Use of Medicine, Medical Utilization and Healthcare Expenditures for Chronic Disease Sufferers*

The goal of this project is to examine the effect of CDHPs on pharmaceutical and medical utilization and overall healthcare expenditures for selected chronic disease sufferers and compare these patterns of care to those observed when members were enrolled in a three-tier pharmacy benefit plan.

Role: *Principal Investigator*, (30% effort), \$79,028

Funding period: 5-01-2005 to 4-30-2006.

Status: *Funded*

**Kaiser Permanente, Colorado**

*The Impact of Prescription Cost-Sharing on Sevelamer Adherence and Clinical Laboratory Outcomes*

The goal of this project is to examine the impact of prescription cost sharing for Sevelamer used for ESRD patients on medication adherence and discontinuation rates in Medicare ESR patients with capped and no cap limits on their prescription benefits.

Role: Co-Principal Investigator, (5% effort for a 6 month period \$3,349), \$33, 920

Funding period: 3-1-2005 to 8-31-2005

Status: *Funded*

**Pfizer Pharmaceuticals**

*Medication switching rates for symptomatic versus asymptomatic disease states: An analysis of impact of prescription copayment differentials and managed care products on medication adherence and switching rates*

The goal of this project is to examine the impact of increasing prescription copayments on switching rates for individuals with asymptomatic disease states compared to those with symptomatic disease states.

Role: Principal Investigator, (20% effort), \$48,800, Funding period: Aug, 04-May 05

Status: *Funded*

**Micromedex, Inc (Greenwood Village, CO)**

*Demonstrating a Return on Investment from Clinical Decision Support Products: A Case Study in Micromedex Products." MICROMEDEX Inc.*

The goal of this project is to examine the impact of drug information databases such as MICROMEDEX products on user opinion and improving patient outcomes.

Role: Principal Investigator, (11% effort), \$29,792

Funding period: 10-7-2003 to 8-31-2004

Status: *Funded*

**Department of Clinical Pharmacy (Seed Grant Program), School of Pharmacy, University of Colorado Health Sciences Center**

*The Impact of the OTC Conversion of Loratadine on Employee Productivity.*

The goal of this project is to examine the impact of the OTC conversion of loratadine (Claritin) on employee productivity for the employees of The University of Colorado Health Sciences Center.

Role: Co-Principal Investigator, (12%-no coverage for effort spent allowed), \$7,380. Funding period: July, 03-February 04

Status: *Funded*

**Schering- Plough Company**

*The Impact of Changes in Prescription Drug Benefits for Second Generation Antihistamines on Utilization and Cost of Therapy*

The goal of this project is to examine the impact of various pharmacy benefit policies surrounding the recent conversion OTC conversion of loratadine (Claritin) on pharmacy and medical utilization and expenditures using members of a large pharmacy benefit manager.

Role: Co-Principal Investigator, (37%) \$88,270, Funding period: December, 03-August, 04

Status: *Funded*

**Quality Care Research Fund, Academic Medicine and Managed Care Forum**

*Evaluating The Effects of Multi-Tiered Pharmacy Benefits on Patient Purchasing Behavior*

The overall goal of this project was to examine the impact of three-tier pharmacy benefit plans on pharmacy utilization, expenditures and consumer behavior. A survey was developed to compare consumer satisfaction among two and three tier plan members along with a comparison of their subsequent pharmacy utilization and costs.

Role: Principal Investigator, (25% effort), \$187,674

Funding period: 8-21-2000 to 12-31-2001

Status: *Funded*

#### **Quality Care Research Fund, Academic Medicine and Managed Care Forum**

*Retrospective Claims Database Analysis of Cholesterol Management in a Managed Care Population.*

The overall goal of the proposed research is to evaluate the appropriateness of cholesterol management with statin therapy and the extent to which LDL goal attainment was achieved in a managed care population

Role: Co-Principal Investigator, (12% effort), \$57,970, Funding period: January, 01-January, 02

Status: *Funded*

#### **American Colleges of Clinical Pharmacy, Primary Care Research Grant**

*Comparison of Lovastatin, Fluvastatin and Pravastatin.*

The overall goal of the proposed research is to compare three low potency cholesterol lowering agents (statins) on their ability to lower LDL levels and facilitate the achievement of target LDL and HDL goal levels.

Role: Co-Investigator, (10% no salary offset), \$10,000, Funding period: October, 00-October, 01

Status: *Funded*

#### **Department of Internal Medicine, School of Medicine, University of Colorado Health Sciences Center, Primary Care Research Grant**

*Evaluating the Continuity of Care for the Uninsured.*

The overall goal of the proposed research is to evaluate the continuity of care with regard to prescription use for enrollees of the Colorado Indigent Care Program as they transition from inpatient to outpatient care.

Role: Co-Investigator, (5%, no coverage for effort), \$5,000, Funding period: January, 00-December,00

Status: *Funded*

#### **Latiolais Leadership Grant Program, The Ohio State University**

*Improving the Performance of P&T Committees.*

The overall goal of the proposed research is to evaluate group performance of Pharmacy and Therapeutic Committees in academic medical centers when making controversial decisions regarding formulary additions.

Role: Co-Investigator, (100% - a graduate student), \$25,000, Funding period: January,98-January, 99

Status: *Funded*

#### **Interdisciplinary Committee on Organizational Studies, University of Michigan Business School**

*An Organizational Model of Group Behavior to Evaluate the Performance of P&T Committees*

The overall goal of the proposed research was to conduct a pilot study to evaluate group dynamics among committee members when making a formulary decision in a hospital setting.

Role: Principal Investigator, (10% - as a graduate student), \$3,000, Funding period: January, 98-December, 98

Status: *Funded*

## PUBLICATIONS

### REFERRED RESEARCH PAPERS/CHAPTERS (PEER REVIEWED):

1. Cabaniss, B., Williams, K, Ward, M., **Nair, KV**. Tackling Quality: It's Never a Level Playing Field Companion Piece to Neurology Outcome Measure Set" (under review by the American Academy of Neurology Board for submission to Neurology Clinical Practice).
2. Gautreaux, J., Coerver, K., **Nair, KV**. Migraine Prevention and Treatment in Children and Adolescents: A Companion Payment Policy Review for Payers (under review by the American Academy of Neurology Board for submission to Neurology Clinical Practice).
3. Piquet, AL. Bennet, JL., Owens, G., Alvarez, EA, Mizenko, C., Sillau, S., **Nair, KV**, Vollmer, TL. A Retrospective, Cross-sectional Study Evaluating Plasma Neurofilament light Chain Levels as a Biomarker in Autoimmune Neurological Disease. Submitted to the Journal of Neuroimmunology. November, 2020.
4. Carlson, KV., Rovner, ER., **Nair, KV.**, Deal, AS., Kristy, RM., Hairston, JC. Persistence with mirabegron or antimuscarinic treatment for overactive bladder syndrome: findings from the PERSPECTIVE registry study. Submitted to the Lower Urinary Tract Symptoms (LUTS). November 2020.
5. **Nair, KV.**, Lipman, L., Flood, K., Jhaveri, M., Licata, S, Noshay, S., Patient-reported outcomes for natalizumab in the treatment of multiple sclerosis: a systematic literature review. Submitted to. Health and quality of life outcomes. November 2020.
6. Adam de Havenon, Alen Delic, Sarah Dehoney, Presely Whetman, Nazanin Sheibani, Brian C. Callaghan, John Ney, Gregory J. Esper, Brandon Magliocco, **Nair, KV**, Five Year Trends in Medicare Part D Payments and Utilization for Neurology Drugs (Accepted). Neurology. January 2021.
7. Nicholas. JA., Shin, RK, Alvarez, EA, Hendin, B, **Nair, KV.**, Lublin, FD., Pandemic Forward: Lessons learned and expert perspectives on multiple sclerosis care in the COVID-19 era (Accepted). Multiple Sclerosis and Related Disorders. December 2020.
8. Vollmer, TL. **Nair, KV**, Williams,I, Alvarez, E. Multiple sclerosis phenotypes as a continuum: the role of neurological reserve. (In press). *Neurology Clinical Practice*. December 2020.
9. Alvarez E, **Nair, KV**, Gorritz M, Bartolome L, Maloney H, Ding Y, Golan T, Wade RL, Kumar R, Su W, Shah R, Russo P, Identification and diagnosis of Secondary Progressive Multiple Sclerosis during the clinical encounter: Results from a physician survey, (revisions) Multiple Sclerosis and Related Disorders, December, 2020.
10. Honce, J. M., **Nair, K. V.**, Hoyt, B. D., Seale, R. A., Sillau, S., Engebretson, E., Schurr, B., Corboy, J. R., Vollmer, T. L., & Alvarez, E. (2020). Brain Atrophy Rates for Stable Multiple Sclerosis Patients on Long-Term Fingolimod versus Glatiramer Acetate. *Frontiers in Neurology*, 11, 1045. <https://doi.org/10.3389/fneur.2020.01045>.
11. Vollmer, B, **Nair, KV**, Sillau, S, Corboy, J, Vollmer, T, Alvarez, E., Rituximab versus Natalizumab, Fingolimod, and Dimethyl Fumarate in Multiple Sclerosis Treatment. *Annals of Clinical and Translational Neurology* 2020 Aug 6;7(9):1466-1476. doi: 10.1002/acn3.51111.
12. Vollmer, T, Cohen, JA, Alvarez, E, **Nair, KV.**, Booster, A et al., Safety results of administering ocrelizumab per a shorter infusion protocol in patients with primary

- progressive and relapsing multiple sclerosis. *Multiple Sclerosis and Related Disorders*; 2020; 46; 102454. <https://pubmed.ncbi.nlm.nih.gov/33045496/>
13. Luis D Medina, Stephanie Torres, Enrique Alvarez, Brooke Valdez and **Nair KV**. Patient-reported outcomes in multiple sclerosis: Validation of the Quality of Life in Neurological Disorders (Neuro-QoLTM) short forms. *Multiple Sclerosis Journal - Experimental, Translational and Clinical*. <https://doi.org/10.1177/2055217319885986>
  14. Carson, KE., Rovner. ER, **Nair, KV**. Anna S. Deal, Rita M. Kristy . Carol R. Schermer Factors Associated with Improvements in Patient Reported Outcomes During Mirabegron or Antimuscarinic Treatment of Overactive Bladder Syndrome: A Registry Study (PERSPECTIVE). *Adv Ther* (2019) 36:1906–1921 <https://doi.org/10.1007/s12325-019-00994-7>.
  15. Honce, JM; **Nair, KV**; Sillau, S; Valdez, B, Miravalle, A; Alvarez, E; Schreiner, T; Corboy, JR; Vollmer, TL A Randomized Study of Rituximab Induction Therapy Followed by Glatiramer Acetate Therapy Compared to Glatiramer Acetate Monotherapy in Multiple Sclerosis. *Neurology*. 2019 Feb 12;92(7):e723-e732. doi: 10.1212/WNL.0000000000006916. Epub 2019 Jan 11.
  16. Vollmer, BL. **Nair, KV.**, Sillau, S., Corboy, JR., Vollmer, TL, Alvarez, E. Natalizumab versus fingolimod and dimethyl fumarate in multiple sclerosis treatment. *Annals of Clinical and Translational Neurology* 2019; 6(2): 252–262. *Annals of Clinical and Translational Neurology* 2019; 6(2): 252–262
  17. Vollmer B, **Nair KV**, Sillau SH, Corboy J, Vollmer T, Alvarez E. Comparison of fingolimod and dimethyl fumarate in the treatment of multiple sclerosis: Two-year experience. *Neurol Clin Pract*. 2018 Aug; 8(4): 292–301.
  18. Vollmer B., Honce J.M., Sillau S., Corboy J.R., Vollmer T., **Nair KV.**, Alvarez E. The Impact of Very Short Transition Times on Switching from Natalizumab to Fingolimod on Imaging and Clinical Effectiveness Outcomes in Multiple Sclerosis. *Journal of Neurological Sciences*. 2018 390; 89-93.
  19. Brandi Vollmer, Daniel Ontaneda, Anasua Bandyopadhyay, Sam Cohn, **Kavita V Nair**, Stefan Sillau, Robert A. Bermel, John R. Corboy, Robert J. Fox, Timothy Vollmer, Jeffrey A. Cohen, Enrique Alvarez, Carrie M. Hersh Discontinuation and comparative effectiveness of dimethyl fumarate and fingolimod in 2 centers *Neurol Clin Pract* Aug 2018, 8 (4) 292-301; DOI: 10.1212/CPJ.0000000000000487
  20. Vollmer, Brandi, **Kavita V Nair**, Stefan H Sillau, John Corboy, Timothy Vollmer, Enrique Alvarez. Comparison of Natalizumab versus Fingolimod and Dimethyl Fumarate in the Treatment of Multiple Sclerosis: Two Year Experience. *Annals of Clinical and Translational Neurology*. 09 December 9<sup>th</sup>, 2018. <https://doi.org/10.1002/acn3.700>
  21. Laura Weinkle, M.A.; Christopher Domen, Ian Shelton, B.A.; Stefan Sillau, Ph.D.; **Kavita Nair**, Ph.D.; Enrique Alvarez, M.D., Ph.D. Exploring cannabis use by patients with multiple sclerosis in a state where cannabis is legal. In press. *Multiple Sclerosis and Related Disorders*. *Mult Scler Relat Disord*. 2019 Jan;27:383-390. doi: 10.1016/j.msard.2018.11.022. Epub 2018 Nov 20.
  22. Trinkley KE, Anderson HD, **Nair KV**, Malone DC, Saseen JJ. Assessing the incidence of acidosis in patients receiving metformin with and without risk factors for lactic acidosis. *Ther Adv Chronic Dis*. 2018; 9:179-90.

23. Effron MB, **Nair KV**, Molife C, Keller SY, Page RL, Simeone JC, Murphy B, Nordstrom BL, Zhu Y, McCollam PL, Vetovec GW., One year clinical effectiveness comparison of Prasugrel with Ticagrelor; Results from a retrospective observational study using an integrated claims database. *Am J Cardiovasc Drugs*. 2018 Apr;18(2):129-141. doi: 10.1007/s40256-017-0255-y.
24. ES Rovner, KV Carlson, AS Deal, **KV Nair**, EE Oakkar, J Park, E Gemmen, .. A Prospective, non-interventional Registry Study of Patients initiating a Course of drug Therapy for overactive bladder (PERSPECTIVE): Rationale, design, and methodology. *Contemporary clinical trials* 2018 Jul;70:83-87.
25. Vollmer, B, **Nair, KV**, Sillau, SH, Corboy, J, Vollmer, T, Alvarez, E., Comparison of Fingolimod and Dimethyl Fumarate in the Treatment of Multiple Sclerosis: Two Year Experience. Accepted. June, 2017 *Multiple Sclerosis Journal: Experimental, Translational and Clinical*. July-September, 2017; [Mult Scler J Exp Transl Clin](#). 2017 Aug 17;3(3):2055217317725102.
26. Foley J, **Nair KV**, Vollmer T, Stephenson JJ, Niecko T, Agarwal SS, Watson C., Long-term natalizumab treatment is associated with sustained improvements in quality of life in patients with multiple sclerosis. [Patient Prefer Adherence](#). 2017 Jun 16;11:1035-1048.
27. McQueen, RB., Farahbakhshian, S; Bell, K; **Nair, KV**, Saseen, JS. Economic Burden of Comorbid Chronic Kidney Disease and Diabetes. [J Med Econ](#). 2017 June;20(6):585-591.
28. Langness, J, Tabano, D, Tise, S, Pratt, L, Ayers, L, Wieland, A, Lin, Sonia, Ghushchyan, V, **Nair, KV**, Everson, GT. Curing Hepatitis C: A Cost Comparison of the Combination Simeprevir Plus Sofosbuvir versus Protease-inhibitor-based Triple Therapy. *Ann Hepatol*. 2017 May - Jun;16(3):366-374. doi: 10.5604/16652681.1235479.
29. Bianca Weinstock-Guttman; **Kavita V Nair**; Joe Glajch; Tanmoy Ganguly, Daniel Kantor, MD, Two Decades of Glatiramer Acetate: From Initial Discovery to the Current Development of Generics. *J Neurol Sci*. 2017 May 15;376:255-259. doi: 10.1016/j.jns.2017.03.030. Epub 2017 Mar 21. Review.
30. Bell, C, Anderson, C, Ganguly, T, Prescott, J, Capila I, Lansing, JC, Sachleben, R, Iyer, M, Fier, I, Roach, J, Storey, K, Miller, P, Hall, S, Kantor, D, Greenberg, BM, **Nair, KV**, Glajch, J. Development of Glatopa® (glatiramer acetate): The First FDA-Approved Generic Disease-Modifying Therapy for Relapsing Forms of Multiple Sclerosis. *Journal of Pharmacy Practice*. Accepted. July, 2017
31. McQueen RB, Ghushchyan V, Olufade T, Sheehan J, **Nair KV**, Saseen JJ. Incremental increases in economic burden parallels cardiometabolic risk factors in the US. *Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy* 2016; 9: 233–241.
32. Dilokthornsakul, P Valuck, RJ, **Nair, KV**, Corboy, JC Allen RR; Campbell, JD. Multiple Sclerosis Prevalence in the United States Commercially Insured Population. *Neurology*. Neurology. 2016 March 15;86(11):1014-21
33. Page, RL, Ghushchyan, V., Van Den Bos, J., Gray, TJ., Hoetzer, G., Bhandary, D, **Nair, KV (senior author)**. The Cost of Inpatient Death Associated with Acute Coronary Syndromes. *Vascular Health and Risk Management*. 3 February 2016 Volume 2016:12 Pages 13—21.
34. A snapshot of Hepatitis C in Colorado. With the Center for Improving Value in HealthCare (CIVHC) Published on May 18, 2015 (available at <http://www.civhc.org/All-Payer-Claims-Database/Resources-and-Reports.aspx/>).



35. Page, RL, Ghuschchyan, V., Allen, RR, Hatsfield, CL., Koch, BR, **Nair, KV (senior author)** Comparative Effectiveness of Ranolazine versus Traditional Therapies in Chronic Stable Angina Pectoris and Concomitant Diabetes Mellitus and Impact on Healthcare Resource Utilization and Cardiac Interventions. *American Journal of Cardiology*;116;9;1; November 2015; 1321-1328.
36. Brett McQueen R, **Nair KV**, Vollmer TL, Campbell JD. Incorporating real-world clinical practice in multiple sclerosis economic evaluations. *Expert Review in Pharmacoeconomics and Outcomes Research*. *Expert Review of Pharmacoeconomics & Outcomes Research*, 2015; 15:6, 869-872
37. Trinkley, KE; Van Matre, ET, Mueller, SW, Page, RL; **Nair, KV**. Perceived Benefit of Teaching Patient Safety to Pharmacy Students by Integrating Classroom Teaching With Introductory (IPPE) Visits. *Journal of Pharmacy Practice*. October 30, 2015 0897190015614478
38. Molife, C; Simone, JC, Marret, E, Tamas, FF, Efron, MB, Nordstorm, BL, Zhu, E, Keller, S, **Nair, KV**, Vetrovec, G, Page, RL, McCollam, PL. One year post discharge resource utilization and treatment patterns of patients with acute coronary syndrome managed with percutaneous coronary syndrome intervention and treated with Ticagrelor or Prasugrel. *American Journal of Cardiovascular Drugs*. October 2015, Volume 15 (5) pp 337-350
39. McQueen, RB; Livingston, T, Vollmer T, Corboy, J, Buckley, B, Allen, RR, **Nair, KV**, Campbell, JD, Increased relapse activity for multiple sclerosis natalizumab users who become non-persistent: a retrospective study *J Manag Care Pharm*. 2015;21(3):210-18
40. Saseen JJ, Ghushchyan, V, **Nair KV**. Comparing Clinical Effectiveness and Drug Toxicity with Hydrochlorothiazide and Chlorthalidone Using Two Potency Ratios in a Managed Care Population *Journal of Clinical Hypertension*. Volume 17, Issue 2, February 2015 Pages 134–140.
41. Tuchscherer, RM; **Nair, KV**, Ghushchyan, V, Saseen JJ; Simvastatin prescribing patterns before and after FDA dosing restrictions: A retrospective analysis of a large healthcare claims database. *American Journal of Cardiovascular Drugs*. February 2015, Volume 15, [1](#) pp 27-34.
42. William V. Padula, Ph.D., M.S.; Mary Beth F. Makic, RN, Ph.D.; Heidi L. Wald, M.D., M.S.P.H.; Jonathan D. Campbell, Ph.D.; **Kavita V. Nair**, Ph.D.; Manish K. Mishra, M.D., M.P.H.; Robert J. Valuck, Ph.D., R.Ph. Hospital-Acquired Pressure Ulcers at Academic Medical Centers in the United States, 2008–2012: Tracking Changes Since the CMS Nonpayment Policy. [The Joint Commission Journal on Quality and Patient Safety](#), Volume 41, Number 6, June 2015, pp. 257-263(7).
43. Thompson, LA; Saseen JJ; O'Bryant, C, Allen, RR, **Nair KV**, Claims analysis of hypertension occurrence, severity changes and patterns of antihypertensive use in cancer patients receiving vascular endothelial growth factor inhibitors. *J Oncol Pharm Pract*. 2015, Vol. 21(4) 258–267
44. William V. Padula, PhD, MS • Manish K. Mishra, MD, MPH • Mary Beth F. Makic, RN, PhD • Heidi L. Wald, MD, MSPH • Jonathan D. Campbell, PhD • **Kavita V. Nair**, PhD. Robert J. Valuck, PhD, RPh. Increased Adoption of Quality Improvement Interventions to Implement Evidence-Based Practices for Pressure Ulcer Prevention in U.S. Academic Medical Centers. *World Views on Evidenced Based Nursing*; 2015; 12-6; 328-336
45. William V. Padula, PhD, MS, • Mary Beth F. Makic, RN, PhD, Manish K. Mishra, MD, MPH • Jonathan D. Campbell, PhD, **Kavita V. Nair**, Heidi L. Wald, MD, MSPH, PhD. Robert J.

- Valuck., Comparative Effectiveness of Quality Improvement Interventions for Pressure Ulcer Preventions in Academic Medical Centers in the United States. [\*The Joint Commission Journal on Quality and Patient Safety\*, Volume 41, Number 6, June 2015, pp. 246 -256](#)
46. Ghushchyan V, **Nair KV**, Page, RL., The Indirect and Direct Costs of Acute Coronary Syndromes With Comorbid Atrial Fibrillation, Heart Failure, or Both. *Vascular Health and Risk Management* 2014 Dec 24;11:25-34.
  47. Page RL, Ghushchyan V, Gifford B, Allen RR, Raut M, Crivera C, Naim, AB, **Nair KV (senior author)**. The hidden costs associated with venous thromboembolism: Impact of lost productivity on employers and employees. *Journal of Occupational & Environmental Medicine*, September 2014 - Volume 56 - Issue 9 - p 979–985
  48. Campbell JD, Ghushchyan V, McQueen RB, Cahoon-Metzger S, Livingston T, Vollmer T, Corboy J, Miravalle A, Schreiner T, Porter V, **Nair KV (senior author)**. Burden of multiple sclerosis on direct, indirect costs and quality of life: national US estimates. *Multiple Sclerosis and Related Disorders*. 2014; 3(2): 227-236.
  49. Wilson, L, **Nair, KV**, Saseen, JJ. Comparison of new-onset gout in adults prescribed chlorthalidone versus hydrochlorothiazide for hypertension *The Journal of Clinical Hypertension*. Volume 16, Issue 12, December 2014, Pages 864–868
  50. Slejko JF, Ho PM, Anderson HD, **Nair KV**, Sullivan PW, Campbell JD. Adherence to statins in primary prevention: yearly adherence changes and outcomes. *Journal of Managed Care Pharmacy* 2014; 20(1): 51-57.
  51. Slejko, JF., Sullivan, PW., Anderson, HD., Ho, PM., **Nair, KV.**, Campbell, JD., Dynamic Medication Adherence Modeling in Primary Prevention of Cardiovascular Disease: A Markov Microsimulation Methods Application. *Value in Health*; 2014; 17;6;725-731
  52. McQueen RB, Ellis SL, Maahs DM, Anderson HD, **Nair KV**, Campbell JD. Frequency of continuous glucose monitoring use and change in hemoglobin A<sub>1c</sub> for adults with type 1 diabetes in a clinical practice setting. *Endocr Pract*. 2014 Oct 1;20(10):1007-15
  53. McQueen RB, Ellis SL, Maahs DM, Anderson HD, **Nair KV**, Libby AM, Campbell JD. Association between Glycated Hemoglobin and Health Utility for Type 1 Diabetes. *The Patient: Patient – Centered Outcomes Research*. 2014;7(2):197-205.
  54. Padula WV, Allen RR, **Nair KV**. Determining the Cost of Obesity and its Common Comorbidities from a Commercial Claims Database. *Clinical Obesity*, 2014 Jan-Feb;4(1):53-58.
  55. Van Matre, E. T., Trinkley, K. E., Mueller, S. W., Page, R. L., **Nair, K. V**. Student perceived benefit of integrating patient safety into a pharmacy curriculum. *In Pharmacotherapy*; 2014; Vol. 34, No. 10, pp. E195-E195).
  56. Tuchscherer, RM; Ghushchyan, V, Allen, RR; **Nair, KV**, Saseen JJ., Simvastatin and CCBs: A Comparison of Prescribing Practices Before and After the U.S. FDA Updates to the 2011 Simvastatin Dosing Standards. *In Journal of Clinical Lipidology*. [May–June, 2014](#), Volume 8, Issue 3, Page 334
  57. Campbell JD, McQueen RB, Miravalle A, Corboy J, Vollmer T, **Nair KV**. Comparative-effectiveness of early natalizumab treatment in JC virus negative relapsing-remitting multiple sclerosis. *Am J Manag Care* 2013; 19(4):278-285.
  58. Slejko JF, Libby AM, **Nair KV**, Valuck RJ, Campbell JD. Pharmacoeconomics and outcomes research degree-granting PhD programs in the United States. *Res Social Adm Pharm*. 2013 Jan;9(1):108-13.

59. Libby AM, Fish DN, Hosokawa P, Linnebur SA, Metz KR, **Nair KV**, Saseen JJ, Vande Griend JP, Vu SP, Hirsch JD. Patient-Level Medication Regimen Complexity Across Populations with Chronic Disease. *Clin Therap* 2013;35(4):385-398.
60. Saseen JJ, Ghushchyan V, Kaila S, Allen RR, **Nair KV**. Achieving Goal Blood Pressures after Switching from Olmesartan to Other Angiotensin Receptor Blockers. *J Clin Hyperten* 2013;15:888–892.
61. Page RL, Ghushchyan V, Gifford B, Allen RR, Raut M, Crivera C, Naim, AB, **Nair KV (senior author)**. Economic burden of acute coronary syndromes for employees and their dependents: Medical and productivity costs. *Journal of Occupational and Environmental Medicine* 2013; 55(7): 761-767.
62. Foley J, Zerkowski K, **Nair KV**. Evidence for Long-term Use of Intramuscular Interferon Beta-1a: An Overview of Relapse, Disability, and MRI Data from Selected Clinical Trials. *J Manag Care Pharm.* 2013;19(1-a):S4-S15.
63. Foley J, Barnes CJ, **Nair KV (senior author)**. Emerging Methods for Evaluating the Effectiveness of Intramuscular Interferon Beta-1a for Relapsing-Remitting Multiple Sclerosis. *J Manag Care Pharm.* 2013;19(1-a):S16-S23.
64. Barnes, CJ, Caon, C, Foley, JF, Friedman, M, Menzin, A, **Nair KV**.,et al., Intramuscular interferon beta-1a and evolving treatment options and outcomes measurement for MS: considerations for managed care.*J Manag Care Pharm.* 2013 Jan-Feb;19(1 Suppl A):S1-53.
65. **Nair, KV (senior author)**., Ghushchyan, V., Naim, A., Effectiveness and Costs of TNF-Alpha Blocker Use for Patients with Rheumatoid Arthritis. [Am Health Drug Benefits](#). 2013 Mar-Apr; 6(2): 126–136.
66. Page, RL, Ghushchyan, G, Allen, RR, Roper, L, Beck, D, Bamron, BH, Tamas, FF, Chan, W, McQueen RB, **Nair, KV (senior author)**. Costs and outcomes associated with clopidogrel discontinuation in Medicare beneficiaries with acute coronary syndrome in the coverage gap. *Drug, Healthcare and Patient Safety*, 2012; 4;67-74.
67. **Nair, KV**, Naim, A., Tang, B, Draghtel, K., Van Den Bos, J. Work Absences and Expenditures for Employees with Autoimmune Inflammatory Diseases. *Journal of Environmental and Occupational Medicine*, 2012; 54;10;1268-1273.
68. Saseen JJ, Agashivala N, Allen RR, Ghushchyan V, Yadao AM, **Nair KV**. Comparison of patient characteristics and gout-related health-care resource utilization and costs in patients with frequent versus infrequent gouty arthritis attacks. *Rheumatology (Oxford)*. 2012 Nov;51(11):2004-12
69. Genevieve Pham-Kanter, G. Caleb Alexander, **Nair KV (senior author)**. Effect of physician payment disclosure laws on prescribing *Archives of Internal Medicine*, 28;172(10):819-21.2012
70. **Nair, KV**., Lawson, KA. Third-party Payment for Prescription Medications in the Retail Sector for the 2nd edition of *Pharmacy Management, Leadership, Marketing, and Finance* (Eds) Chisholm-Burns, MA., Vaillancourt, AM, Shepard, M. in *Pharmacy Management, Leadership, Marketing, And Finance*. 2<sup>nd</sup> Edition pp 251 to 271. 2013
71. Alford JC, Saseen JJ, Allen RR, **Nair KV**. Persistent use of against-label statin-fibrate combinations from 2003-2009 despite United States food and drug administration dose restrictions. *Pharmacotherapy*. 2012 Jul;32(7):623-30.
72. Pesa, JA., VanDenBos, J., Gray T, Harsig, C, McQueen, RB, Saseen, JJ, **Nair, KV (senior author)**. An evaluation of the impact of patient cost sharing for antihypertensive

- medications on adherence, medication and health care utilization, and expenditures. *Patient Preference and Adherence*; 2012; 6;63-72.
73. Abbott Z, **Nair KV**, Allen RR, MS, Akuthota V. 2011 Utilization characteristics of spinal interventions. *The Spine Journal: Official Journal of the North American Spine Society*. 12(1):35-43, 2012
  74. Page, R., Ghushchyan, V., **Nair KV (senior author)**. A Call to Action: Responding to the Future Forecasting of Cardiovascular Disease in America. *American Journal of Health and Drug Benefits*. Am Health Drug Benefits 2011;4(5):280-288.
  75. Brett Pinsky, MPH, James Harnett, PharmD, MS, Ryne Paulose-Ram, PhD, Jack Mardekian, PhD, **Nair, KV (senior author)**., PhD. A Claims-Based Analysis Evaluating the Impact of Treatment by NCQA-Certified Physicians on Diabetes-Related Outcomes. *American Journal of Health and Drug Benefits*. Nov/Dec 2011.
  76. **Nair KV**, Ghushchyan V, Van Den Bos J, Halford ML, Tan G, Frech-Tamas FH, Doyle J. Burden of Illness for an Employed Population with Chronic Obstructive Pulmonary Disease. *Population Health Management*. 2012; 15 Mar 8.
  77. **Nair, KV.**, John Corboy, MD;K. H. Kahler, PhD; Richard Read Allen, MS; Vahram Ghushchyan, PhD; Robert Brett McQueen, MS; Jacqui Bainbridge, PharmD; H. Dastani, PhD; Nikita Mody Patel, PharmD Use of Diagnostic Tests and Procedures for Disease-Modifying Therapy (DMT) Users and Non-DMT Users with Multiple Sclerosis." in *Expert Review of Neurotherapeutics*, Jun 2011, Vol. 11, No. 6, Pages 787-798.
  78. **Nair K.V.**, PhD; Jan S., PharmD ; Belletti D.A., MA; Doyle J.J., RPh; Allen R.R., MS; McQueen R.B., MS; Saseen J.J., PharmD; Vande Griend, JP, PharmD, Patel J.V., MBA. Understanding Barriers to Medication Adherence for the Hypertensive Population by Evaluating Responses to a Telephone Survey *Journal of Patient Preference and Adherence* 2011;5 195–206
  79. **Nair, KV.**, Tang, B., Naim, A., Draaghtel, K., Van Den Bos, J., Work Absences and Expenditures for Employees with Rheumatoid Arthritis Treated with Anti-Tumor Necrosis Factor Agents. In Press. *Journal of Health and Productivity*; July, 2012; 13-21
  80. **Nair, KV**, Jan S., Saseen, JJ., Allen. Pre and Post Impact of Part D on Utilization and Expenditures in 2005 and 2006. *Journal of Healthcare Finance*, 56-64, Winter, 2011
  81. Hanselin, MR., Saseen, JJ., Allen, RR., Maars, JC., **Nair, KV**. Description of anti-hypertensive use in patients with resistant hypertension prescribed four or more agents. *Hypertension* 2011;58:1008-1013.
  82. McQueen, RB., Ellis, S., Campbell, JD., **Nair, KV.**, Sullivan PW. Cost-Effectiveness of Continuous Glucose Monitoring and Intensive Insulin Therapy for Type 1 Diabetes *Cost Effectiveness and Resource Allocation*. 2011; 9:13; 1-8.
  83. **Nair, KV.**, Jan, S., Wolfe, P., Allen, RR, Saseen, JJ., Impact of Medicare Part D on Utilization and Expenditures. *Am J Pharm Benefits*. 2010;2(3):209-218
  84. **Nair KV**, Miller K, Saseen J, Wolfe P, Allen RR, Park J. Prescription Copay Reduction Program for Diabetic Employees: Impact on Medication Compliance and Healthcare Costs and Utilization. *American Health & Drug Benefits* 2009. January, Vol (2) No. 1.
  85. **Nair, KV.**, Lawson, KA. Third part payment for prescription medications in the retail section; Chapter 9 (Section 4), in "*Essentials of Pharmacy Management, Leadership, Marketing, and Finance*." Eds. Chisholm-Burns, A., Villiancourt, AM., Shepard M. Jones and Bartlett Publishers, Sudbury, Massachusetts, 2010.

86. **Nair, KV.**, (Stakeholder Perspective) for Orphan Drug Pricing and Payer Management in the United States: Are We Approaching the Tipping Point? Hyde; R., Dobrovolny D. *American Journal of Health and Drug Benefits*. January/February 2010, Vol 3, No 1, p 17-24.
87. Bharadwaja, B., Carroll, N., Korner, E, **Nair, KV (senior author)**. Impact of prescription benefit coverage limits on sevelamar hydrochloride adherence for patients with ESRD. *American Journal of Health and Drug Benefits*. September/October 2009; 2; 6 ;242-249.
88. **Nair, KV**, Miller, K, Saseen JJ, Wolfe, PW, Park, J. The Impact of Reducing Prescription Copays on Utilization and Expenditures for Diabetics. *American Journal of Health and Drug Benefits*. January 2009; 21 ;14-42.
89. **Nair, KV**. Value based benefit design in Oncology. Editorial. *American Journal of Health and Drug Benefits* February, 2009.
90. **Nair, KV**, Ghushchyan, V., Saseen, JJ. HRA based Consumer Driven Health Plans (CDHPs):Their Impact on Medical Utilization, Pharmacy Utilization and Expenditures. *Journal of Healthcare Finance*. 2008; Fall; 35 (1); 1-12.
91. R Lee Page, P Barton, **KV. Nair**.Effect of cost-sharing for prescription medications on health outcomes in older adults: a critical review of the literature and potential implications for managed care.The Consultant Pharmacist® 2008; 23 (1), 44-54
92. **Nair KV**, Tang, B, Vandebos, J et al., Categorization of Infliximab Dose Changes and the Influence on Healthcare Utilization and Expenditures for Patients with Rheumatoid Arthritis in Medicare and Commercially Insured Populations. Current Research and Medical Opinion. *Current Medical Research and Opinion*, 2008; Vol. 25 (2), Pages 303-314.
93. **Nair, KV**, Park, J, Wolfe, P et al., Consumer-driven health plans: Impact on utilization and expenditures for chronic disease sufferers. *Journal of Occupational and Environmental Medicine*; May 2009; 51; 5; 594-604
94. **Nair, KV**, Saseen, JJ. Quality Assessment of Dyslipidemia in Managed Care: Using Current Best Evidence as a Benchmark for Quality. *Annals of Pharmacotherapy* 2006, 40 (1); 124-127
95. Shrank, WH., Hoang, T., Ettner, SL., London, R., DeLapp, D., **Nair, KV.**, Glassman, P., Asch, SM. The implications for choice: prescribing generic or preferred branded medications improves adherence for chronic medications. *Archives of Internal Medicine* 2006;166 (3);332-337
96. Davidson, J., **Nair, KV.**,Valuck, RJ., Moore, G. Evidenced based medicine in the Pharmacy. *Patient Safety and Quality Healthcare*. March/ April 2006.
97. Sullivan, PW, **Nair, KV**, Patel, B., The Impact of Changes in Prescription Drug Benefits for Second-Generation Antihistamines on Utilization And Cost of Therapy. *American Journal of Managed Care*. 2005; June;11;374-382.
98. **Nair KV**, Valuck, RJ., Allen, RR., Lewis, SJ. Impact of Increased Copayments on the Discontinuation/Switching Rates of Non Formulary Medications. *Journal of Pharmacy Technology*. May/June. 21 (3); 2005.
99. **Nair, KV**. Prescription to OTC Switch of Second-Generation *Antihistamines: Impact on Healthcare Costs and Resource Utilization*. 2006. Disease Management & Health Outcomes. 14 (92); 69-74.
100. **Nair, KV**, Sullivan, PW., Therapeutic and Economic Consequences of the OTC Conversion of Loratadine. *Annals of Pharmacotherapy*. 2004; 38 (1); 169-171

101. **Nair, KV**, Valuck, RJ. Consumer Responses to a Pharmacy Benefit Report Card. *Journal of Healthcare Finance*. 2004; 3 (1); 55-72.
102. **Nair, KV**, Valuck, RJ., Impact of Three-Tier Pharmacy Benefit Structures on Consumer Attitudes and Drug Utilization and Costs: A Critical Review. *Disease Management and Health Outcomes*. 2004; 12 (2); 181-92.
103. Ganther JM, **Nair KV.**, Valuck RJ, McCollum M, Lewis SJ Consumer Attitudes and Factors Related to Prescription Switching Decisions in Multi-tier Copayment Drug Benefit Plans. 2004. *Am J Manage Care*. March. 10 (3); 210-208.
104. Valuck RV., Williams, SA., MacArthur, M., Saseen, JJ., **Nair, KV.**, McCollum, MM., Ensor, JE., A retrospective cohort study of correlates of response to pharmacologic therapy for hyperlipidemia in members of a managed care organization. *Clinical Therapeutics* .2003. 25 (11) pp 2936-2957.
105. **Nair, KV.**, Can consumer attitudes predict prescription purchasing behavior? *Managed Care Interface*. 2003; 16 (6); 22-33.
106. Nair KV., Wolfe P, Valuck RJ, McCollum M, Ganther, JM. Lewis SJ. Effects of a Three Tier Pharmacy Benefit Design on the Prescription Purchasing Behavior Of Individuals with Chronic Disease States. *J Manage Care Pharm*, 2003; (Mar/April); 9 (2); 479-489.
107. **Nair KV.**, Ganther JM, Valuck RJ, McCollum M, Lewis SJ. Impact of multi-tiered pharmacy benefits on attitudes of patients with chronic disease states *J Manage Care Pharm*, 2002; (Nov/Dec); 8 (6); 477-493.
108. Valuck RV and **Nair, KV**. Chapter 5: Drug Use and the Healthcare System. In: *Pharmaceutical Care*, 2<sup>nd</sup> Edition. 2002. pp 77-99. Eds Knowlton, C and Penna, P. American Society of Health System Pharmacists. Bethesda, MD
109. **Nair KV**, Ganther JM, Valuck RJ, McCollum M, Lewis SJ. Improving formulary compliance with managed care members. *Drug Benefit Trends*. 2002;14(7):44-46.
110. **Nair, KV**. Evaluation of Health and Pharmacy Benefit Information in Health Plan Information Packages. *Managed Care Interface*, 2001; 14 (12); 51-54.
111. **Nair, KV**. Consumerism and Pharmacy Benefit Plans. *Drug Benefit Trends*, 2001; 13 (11); 21-26.
112. **Nair, KV**, Ascione, FJ. Examining the Activities of P&T Committees: An Exploratory Study. *Journal of Pharmaceutical Marketing and Management*. 2001; 14 (2); 1-29.
113. **Nair, KV.**, Ascione, FJA. An organizational tool to evaluate the organizational determinants of P&T Committee performance *Journal of the American Pharmaceutical Association*, 2001; 41 (4); 608-619.
114. **Nair, KV**, Ascione, FJ. Evaluation of the Performance of P&T Committees: An Exploratory Study: *Formulary*. 2001; 36 (2); pp 136-146.
115. **Nair, KV.**, Coombs, J. Ascione, FJA. Assessing the structure, activities and functioning of P&T Committees: A multi-site case study. *P&T*, Oct 2000; pp 516-525.
116. **Nair, KV**. Gaither, CA. Effects of work, non-work, and role conflict on the overall life satisfaction of pharmacy faculty. *American Journal of Pharmaceutical Education*. 63(1): p 1-11. 1999.

**POSTER (including published abstracts)/PODIUM PRESENTATIONS**

1. Piquet, AL, Alvarez, E., Bennett, JL, Knapp, C., Sillau, S, Mizenko, C., **Nair, KV.**, Vollmer, TL. A Retrospective, Cross-Sectional Study Evaluating Plasma Neurofilament Light Levels in Autoimmune Encephalitis Poster presentation at the American Neurological Association. 145th Virtual Annual Meeting of the American Neurological Association, October 4–9, 2020.
2. **Nair, KV.**, Mehta, R., Pham, ., Halpern, R., Le, Lisa, Frazer, M. Identification of Persons With Multiple Sclerosis and Prevalence of Expanded Disability Status Scale Assessment in an Electronic Health Record Database. Poster presentation for 2020 Oct 19-23, 2020
3. Ritchie, A., Selva, S, Owens, G., Knapp, Gonzalez, Alvarez, EA, **Nair, KV**, Vollmer, TL., Determining the effect of blood anticoagulants on the detection level of neurobiomarkers in headache and control patients on the SIMOA platform. Poster presentation at the virtual ACTRIMS/ECTRIMS 2020 meeting, September 11-13, 2020
4. Robert Gross, Alanna Ritchie, Stefan Sillau<sup>1</sup>, **Nair, KV**, Courtney Knapp, Sean Selva, Greg Owens, J.L. Bennett, Enrique Alvarez<sup>1</sup>, Timothy L. Vollmer. A cross-sectional exploration of four CSF and plasma biomarkers across headache, multiple sclerosis, and neuromyelitis optica spectrum disorder. Poster presentation at the 2020 American Academy of Neurology Virtual Meeting. April 25- May 1, 2020.
5. Robert Gross, Alanna Ritchie, Sean Selva, Jose Parra Gonzalez, Courtney Knapp, Stefan Sillau, Greg Owens, **Nair, KV**, Timothy Vollmer, Enrique Alvarez. Monitoring Multiple Sclerosis Treatment with Plasma Biomarkers: NfL, GFAP, UCH-L1, and Tau. Poster presentation at the virtual ACTRIMS/ECTRIMS 2020 meeting, September 11-13, 2020
6. Brandi Vollmer, Anthony Declusin, **Nair, KV** Stefan Sillau, John Corboy, Timothy Vollmer, Enrique Alvarez. Ocrelizumab real-world safety and effectiveness in the two years of treatment in multiple sclerosis. Poster presentation at the virtual ACTRIMS/ECTRIMS 2020 meeting, September 11-13, 2020.
7. Jacob Leary, Stefan Sillau, Brandi Vollmer, **Nair KV**, Timothy Vollmer. Patient demographics and disease characteristics predict likelihood of clinical benefit on patient-reported outcome measures in multiple sclerosis. Poster presentation at the virtual ACTRIMS/ECTRIMS 2020 meeting, September 11-13, 2020.
8. Alvarez, E., **Nair, KV**, Vollmer, T.M Bennett, JL., et al., Evaluating the Correlation Between Spinal Fluid and Blood Levels of Neurofilament Light, GFAP, Tau, and UCHL1: Do We Need a Correction Factor in Evaluating Blood Levels? Poster presentation at the at the 2020 American Academy of Neurology Virtual Meeting. April 25- May 1, 2020.
9. Alvarez, E, Gendelman, S., **Nair, KV.**, Vollmer, B et al, A Year and Half of Real World Efficacy and Safety od Ocrelizumab in The Treatment of Multiple Sclerosis. Poster presentation at the at the 2020 American Academy of Neurology Virtual Meeting. April 25- May 1, 2020.
10. Natalie J. Engmann<sup>1</sup>, Daniel Sheinson<sup>1</sup>, Erru Yang<sup>1</sup>, Damian Fiore<sup>1</sup>, Enrique Alvarez<sup>2</sup>, **Nair, KV**, Timothy L. Vollmer: Real-world outcomes with ocrelizumab compared with other disease-modifying therapies in US commercial claims databases. Poster presentation at the 2020 American Academy of Neurology Virtual Meeting. April 25- May 1, 2020.
11. Alvarez, E, Nair, KV., Ritchie, A., Shelton, I., Gendelman, I, Sillau, S., Owens, G. Vollmer, T., Serum neurofilament levels in long term rituximab treated multiple sclerosis patients: are we over or under treating? Presented at the ECTRIMS Annual Meeting, Stockholm, Sweden, September 9-12, 2019.



12. Amanda Piquet<sup>1</sup>, Enrique Alvarez<sup>1</sup>, Jeffrey Bennett<sup>2</sup>, Courtney Knapp<sup>1</sup>, Stefan Sillau<sup>1</sup>, **Nair, KV** Timothy Vollmer<sup>1</sup>. A Retrospective, Cross-sectional Study Evaluating Plasma Neurofilament Light Levels in Autoimmune Encephalitis. Poster presentation at the 2020 American Academy of Neurology Virtual Meeting. April 25- May 1, 2020.
13. Leary, JB, Sillau, S., Vollmer B., **Nair, KV.**, Vollmer, TV. Patient demographic factors, but not disease characteristics or brain volumes, predict likelihood of improvement on patient-reported outcome measures in multiple sclerosis. Podium presentation at the 2020 Western Medical Research Conference January 23-25, 2020 Carmel, California
14. T Vollmer E Alvarez, **KV Nair**. Evaluation of Shorter Infusion Times With Ocrelizumab in Patients With Multiple Sclerosis. . American Academy of Neurology 2019 Annual Meeting. Philadelphia, Pennsylvania. May 4-11, 2019.
15. Enrique Alvarez, MD/PhD K , **Nair KV**, Ian T. Shelton<sup>1</sup> et al., Evaluating the Tolerability and Safety of Switching from Rituximab to Ocrelizumab: Infusion Related Reactions in Relapsing Forms of Multiple Sclerosis. American Academy of Neurology 2019 Annual Meeting. Philadelphia, Pennsylvania. May 4-11, 2019.
16. Vollmer, Brandi, **Nair, KV**, Stefan H Sillau, Timothy Vollmer, John Corboy, Enrique Alvarez. Higher efficacy therapies appear to have a disproportionately larger effect in younger patients with multiple sclerosis. American Academy of Neurology 2019 Annual Meeting. Philadelphia, Pennsylvania. May 4-11, 2019.
17. Vollmer, Brandi, **Nair, KV** John Corboy, Timothy Vollmer, Enrique Alvarez. Characteristics of patients switching from anti-CD20 therapy to natalizumab in the treatment of multiple sclerosis. American Academy of Neurology 2019 Annual Meeting. Philadelphia, Pennsylvania. May 4-11, 2019.
18. Alimohamadi, Sahar, Brandi Vollmer, **Nair, KV**, Stefan H Sillau, John Corboy, Timothy Vollmer, Enrique Alvarez. Ocrelizumab safety and effectiveness in the one year treatment of multiple sclerosis compared to other disease modifying therapies. American Academy of Neurology 2019 Annual Meeting. Philadelphia, Pennsylvania. May 4-11, 2019.
19. Hersh, Carrie, Brandi Vollmer, Haleigh C Harris, **Nair, KV**, Robert A Bernal, John Corboy, Robert J Fox, Timothy Vollmer, Jeffrey A Cohen, Daniel Ontaneda, Enrique Alvarez. Discontinuations and comparative effectiveness of dimethyl fumarate and fingolimod in two large academic medical centers at 36-month follow-up. American Academy of Neurology 2019 Annual Meeting. Philadelphia, Pennsylvania. May 4-11, 2019.
20. T Vollmer E Alvarez, **KV Nair**, J Cohen, A Boster, D Masterman, A Pradhan, J Pei, M Yang, A Bobbala, B Moss. Design of a study to evaluate the safety of administering ocrelizumab per a shorter infusion protocol in patients with primary progressive multiple sclerosis and relapsing multiple sclerosis. 26<sup>TH</sup> Annual meeting of the European Charcot Foundation. November 15-17, 2018, Baveno, Italy.
21. Vollmer, Brandi, **KV Nair**, Stefan H Sillau, John Corboy, Timothy Vollmer, Enrique Alvarez Comparison of Rituximab vs Fingolimod, Dimethyl Fumarate and Natalizumab in the Treatment of Multiple Sclerosis: Two Year Experience. Poster presentation at the European Committee for Treatment and Research in Multiple Sclerosis 2018 Annual Meeting. Berlin, Germany. October 10-12, 2018.
22. Vollmer, Brandi, **KV Nair**, Stefan H Sillau, John Corboy, Timothy Vollmer, Enrique Alvarez Assessing the Safety and Effectiveness of Rituximab in the Treatment of Multiple Sclerosis.



- Poster presentation at the European Committee for Treatment and Research in Multiple Sclerosis 2018 Annual Meeting. Berlin, Germany. October 10-12, 2018.
23. J.M Honce, **K.V Nair**, S.H Sillau, B Vollmer, T Vollmer, E Alvarez .Predicting which patients with multiple sclerosis will develop a progressive course using patient information and clinically obtained brain volumes. Poster presentation at the European Committee for Treatment and Research in Multiple Sclerosis 2018 Annual Meeting. Berlin, Germany. October 10-12, 2018.
  24. Honce, **KV. Nair**, B. Hoyt, S. Sillau, J. Corboy, T. Vollmer. Comparison of 24 month changes in brain volume among long term users of fingolimod versus glatiramer acetate in patients with multiple sclerosis. Poster presentation at the European Committee for Treatment and Research in Multiple Sclerosis 2018 Annual Meeting. Berlin, Germany. October 10-12, 2018.
  25. I. Shelton, N. Zanganeh, S. Selva, S. Sillau, **KV. Nair**, T Vollmer, E. Alvarez, Characterizing cytokine changes before and after ocrelizumab infusions and their contribution to infusion related reactions. Poster presentation at the European Committee for Treatment and Research in Multiple Sclerosis 2018 Annual Meeting. Berlin, Germany. October 10-12, 2018.
  26. Hersh, CM., Vollmer, B., Bandyopadhyay, S. Cohn, K, **Nair, KV** et al., Comparative effectiveness and discontinuation of dimethyl fumarate and fingolimod in two large academic medical centers at 24-month follow-up: summary of sub-group analyses. Poster presentation at the *American Academy of Neurology 70th 2018 Annual Meeting*. Los Angeles, California. April 21-27, 2018.
  27. Laura Weinkle M.S.<sup>1</sup>, Ian Shelton B.S<sup>1</sup>, Stefan Sillau Ph.D<sup>1</sup>, Christopher Domen Ph.D<sup>2</sup>, **Nair KV.**, , Enrique Alvarez M.D, Ph.D<sup>1</sup>. Exploring Cannabis use by Patients with Multiple Sclerosis in a state where Cannabis is legal. Poster presentation at the *American Academy of Neurology 70th 2018 Annual Meeting*. Los Angeles, California. April 21-27, 2018
  28. N. Zanganeh, S. Selva<sup>1</sup>, **Nair, KV**, T. Vollmer, E. Alvarez. Cytokine changes induced by antiCD20 Infusions: A Comparison of Rituximab Versus Ocrelizumab " Poster presentation at the *American Academy of Neurology 70th 2018 Annual Meeting*. Los Angeles, California. April 21-27, 2018.
  29. **Medina, L. D.**, Wedeman, B., Alvarez, E., Nair, K., & Hoyt, B. (2018). *Disease modifying treatments in MS and their differential impact on cognition*. 46<sup>TH</sup> Annual Meeting, International Neuropsychological Society Annual Meeting, February 14-17 Washington, DC
  30. N. Zanganeh<sup>1</sup>, S. Selva<sup>1</sup>, K. **Nair, KV**, T. Vollmer<sup>1</sup>, E. Alvarez<sup>1</sup>. Characterizing the cytokine profile before and after antiCD20 infusions: c comparison of rituximab versus Ocrelizumab. Poster Presentation (P776) *the 7<sup>th</sup> Joint ACTRIMS-ECTRIMS Meeting. Paris, France, October 26-28<sup>th</sup>. 2017. Multiple Sclerosis Journal 2017; 23: (S3) 85–426*
  31. B.L. Vollmer, **Nair, KV**, S. Sillau<sup>1</sup>, J. Corboy, T. Vollmer<sup>1</sup>, E. Alvarez. Comparison of natalizumab vs fingolimod and dimethyl fumarate in the treatment of multiple sclerosis: two year experience. Poster Presentation (EP1632) *at the 7<sup>th</sup> Joint ACTRIMS-ECTRIMS Meeting. Paris, France, October 26-28<sup>th</sup>. 2017. Multiple Sclerosis Journal 2017; 23: (S3) 85–426*
  32. Medina, L. D., **Nair, KV.**, Valdez, B., Alvarez, E., & Vollmer, T. (2017). Profiles of patient-reported outcomes as predictors of treatment type in multiple sclerosis: A discriminant function analysis of disease modifying treatment. Joint European Committee for Treatment

- and Research in Multiple Sclerosis – Americas Committee for Treatment and Research in Multiple Sclerosis Meeting. Paris, France
33. **Nair, KV**, Vollmer, T et al., Natalizumab Treatment is Associated with Improved Patient-Reported Outcomes in the Treatment of Multiple Sclerosis: Results from a Systematic Literature Review. E Poster Presentation at the 7<sup>th</sup> Joint ACTRIMS-ECTRIMS Meeting. October 26-28<sup>th</sup>. 2017. *Paris, France, October 26-28<sup>th</sup>. 2017. Multiple Sclerosis Journal* 2017; 23: (S3) 85–426
  34. Hersh, CM., Vollmer, B., Bandyopadhyay, S. Cohn, **Nair, KV** et al., Comparative Effectiveness of Discontinuation of Dimethyl Fumarate and Fingolimod in Two Large Academic Medical Centers at 24 Month Follow Up. Poster Presentation (P663) at the 7<sup>th</sup> Joint ACTRIMS-ECTRIMS Meeting. Paris, France, October 26-28<sup>th</sup>. 2017. *Multiple Sclerosis Journal* 2017; 23: (S3) 85–426
  35. Vollmer, Brandi, **Kavita Nair**, Stefan H. Sillau, John Corboy, Timothy Vollmer, Enrique Alvarez. Comparison of Natalizumab vs Fingolimod and Dimethyl Fumarate in the Treatment of Multiple Sclerosis: *Two Year Experience*. *American Academy of Neurology 2017 Annual Meeting*. Boston, Massachusetts. April 22-28, 2017.
  36. Sarah M Planchon, Brandi Vollmer, Uriel Kim, Stefan Sillau, Hong Li, Radhika Rastogi, Sudarshana M, Dattanand, Cecilia Vieira da Silva, **Kavita Nair**, Daniel Ontaneda, Enrique Alvarez. Real World Effectiveness of First-Line Use of Gilenya: A Two-Site Retrospective Study. *American Academy of Neurology 2017 Annual Meeting*. Boston, Massachusetts. April 22-28, 2017.
  37. Vollmer, B, **Nair, KV**, Sillau, S, Corboy JH; Vollmer, TL, Alvarez, E Comparison of Fingolimod and Dimethyl Fumarate in the Treatment of Multiple Sclerosis: Two Year Experience. *Poster presentation at the 32<sup>nd</sup> Congress of the European Committee for the Treatment and Research in Multiple Sclerosis (ECTRIMS). 21<sup>ST</sup> Annual Conference (14-17 September, London, United Kingdom)*. *Multiple Sclerosis Journal*. Volume 22, Issue 3\_suppl, pp 341; September 2016
  38. Honce JM, MD, **Nair KV**, Sillau, S, Vollmer B, Vollmer T, Alvarez E. Predicting which patients with multiple sclerosis will develop a progressive course using patient information and clinically obtained brain volumes. *Poster presentation 32<sup>nd</sup> Congress of the European Committee for the Treatment and Research in Multiple Sclerosis (ECTRIMS). 21<sup>ST</sup> Annual Conference (14-17 September, London, United Kingdom)*. *Multiple Sclerosis Journal*. Volume 22, Issue 3\_suppl, pp 510; September 2016
  39. Vollmer, B, Kim C.H., Campbell, JD, Corboy, JH, Vollmer, TL, **Nair, KV. (senior author)**. Evaluating the increase in the cost of Multiple Sclerosis drugs in the United States between 2010-2015: Market price vs inflation based analysis. *Poster presentation at the 32<sup>nd</sup> Congress of the European Committee for the Treatment and Research in Multiple Sclerosis (ECTRIMS). 21<sup>ST</sup> Annual Conference (14-17 September, London, United Kingdom)*. *Multiple Sclerosis Journal*. Volume 22, Issue 3\_suppl, pp 462; September 2016
  40. Honce, JH; **Nair, KV**; Sillau, S; Valdez, B, Torok, I, Miravalle, A; Alvarez, E; Schreiner, T, Bennett, J, Corboy, JC Vollmer, TL, Comparing Rituximab Induction Therapy Followed by Glatiramer Acetate Therapy to Glatiramer Acetate Monotherapy in MS Patients on Clinical and Imaging Outcomes. *Poster presentation 32<sup>nd</sup> Congress of the European Committee for the Treatment and Research in Multiple Sclerosis (ECTRIMS). 21<sup>ST</sup> Annual Conference (14-17*

- September, London, United Kingdom). Multiple Sclerosis Journal. Volume 22, Issue 3\_suppl, pp 620; September 2016
41. **Nair KV (senior author)**, Sillau, S, Faircough, DF, Miller, D, Foley, J, Valdez B, Engerbretson, B, Wedemen, B, Hosford, L, Hoyt, T, Seawright, L, Corboy, CJ, Livingston, T. Comparing Neuro-QOL Outcomes in a 2 year longitudinal assessment of new users of natalizumab and fingolimod with MS. E poster at *the 32<sup>nd</sup> Congress of the European Committee for the Treatment and Research in Multiple Sclerosis (ECTRIMS). 21<sup>ST</sup> Annual Conference (14-17 September, London, United Kingdom)*. Multiple Sclerosis Journal. Volume 22, Issue 3\_suppl pp 818 September 2016
  42. Kim C.H., Brandi Vollmer, Jon Campbell, John Corboy MD, Timothy Vollmer MD, **Kavita V. Nair (Senior author)**. Comparing the Increase in the Cost of Drug Prices Among Multiple Sclerosis Drugs: Anticipated vs. Market Prices Between 2010-2015. **Poster presentation at ISPE's 32nd International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE) August 25-28, 2016 Dublin, Ireland.**
  43. Brian Hoyt, Justin H, Honce, Stefan H Silau, Brittany Wedeman, Eric Engerbretson, Kristen Johnson, Nadia Tenenbaum, MD, Vivian Herrera, Lisa Siconolfi, PhD, Enrique Alvarez, **Kavita V. Nair, (senior author)** Preliminary Comparison of Baseline Cognition and Correlations with PROs of FTY Versus GA in MS Patients in a Longitudinal Observational Study" Poster presentation at the *2016 Annual Meeting of the Consortium of Multiple Sclerosis Centers (CMSC), June 2-4, Maryland*
  44. Ontaneda D, Vollmer B, Silau S, Cohn S, **Nair KV**, Bermel R, Vollmer T, Fox RJ, Corboy J, Cohen JA, Hersh C, Alvarez E. Comparative efficacy and discontinuation of fingolimod and dimethyl fumarate in two large academic medical centers. Poster Session P3 on 4/18/2016 at the 68<sup>th</sup> AAN Annual Meeting April 15-21, 2016, at the Vancouver Convention Centre in Vancouver, BC, Canada. *Neurology April 5, 2016 vol. 86 no. 16 Supplement P3.109*
  45. Justin Honce, MD, **Nair, KV**, Brian Hoyt, PhD, Stefan H Silau, PhD, Brittany Wedeman, BS, Eric Engerbretson, BA, Brandi Vollmer BS, Kristen Johnson, PhD/MPH, Nadia Tenenbaum, MD, Vivian Herrera, MPH, Lisa Siconolfi, PhD, Augusto Miravalle MD, Jeffrey L Bennett, MD/PhD, Teri Schreiner, MD, John Corboy MD, Timothy Vollmer MD, Enrique Alvarez MD/PhD. Comparison of Baseline Characteristics of Glatiramer Acetate Versus Fingolimod in Multiple Sclerosis Patients on Brain Volume, Cognition and Neuro-QOL Outcomes: Preliminary Analysis of a Longitudinal Observational Study" Poster Session P6 on 4/21/2016 at the 68<sup>th</sup> AAN Annual Meeting April 15-21, 2016, at the Vancouver Convention Centre in Vancouver, BC, Canada. *Neurology April 5, 2016 vol. 86 no. 16 Supplement P6.170*
  46. Alvarez, EA; Vollmer, B; Sillau, S; **Nair, KV**; Corboy, JH; Vollmer TL, Honce, JH. The Impact of Very Short Transition Times on Switching from Tysabri to Gilenya on Imaging and Clinical Effectiveness Outcomes". Poster presentation P2 on 4/17/2016 at the 68<sup>th</sup> AAN Annual Meeting April 15-21, 2016, at the Vancouver Convention Centre in Vancouver, BC, Canada. *Neurology April 5, 2016 vol. 86 no. 16 Supplement P2.110*
  47. Vollmer, B; Nair, KV; Sillau, S; **Nair, KV**; Corboy, JH; Vollmer TL; Alvarez, E Comparison of Fingolimod and Dimethyl Fumarate in the Treatment of Multiple Sclerosis: Two Year Experience" Podium presentation. Session S24: Clinical Outcomes and Treatment Strategies in Multiple Sclerosis on Monday, 4/18/2016 at 4:15:00 PM - 4:30:00 PM at the 68<sup>th</sup> AAN Annual Meeting April 15-21, 2016, at the Vancouver Convention Centre in Vancouver, BC, Canada. *Neurology April 5, 2016 vol. 86 no. 16 Supplement S24.004 (Platform session)*

48. RB McQueen; S Farahbakhshian; K Bell' **KV Nair**; J Saseen- PHS2—Economic Burden Of Moderate Chronic Kidney Disease In Type 2 Diabetes; *Value in Health Volume 19, Issue 3, May 2016, Pages A14.*
49. Daniel Ng, Carol Schermer, Rita Kristy, Natalia Flores, Jonathan Chapnick, **Kavita V. Nair, PhD**; Kathy Gooch, PhD. Description of Caregivers of Older Adult Patients with Overactive Bladder: An Observational Study” Poster Presentation to 2016 Annual Scientific Meeting of the American Geriatrics Society (AGS) from May 19 – 21 (at the Long Beach Convention and Entertainment Center in Long Beach, California. *Journal of the American Geriatric Society. Vol. 64.*
50. Daniel B. Ng, Natalia M. Flores, **Kavita V. Nair**, Rita Kristy, Jonathan Chapnick, Katherine Gooch, Carol Schermer· The Humanistic Impact of Overactive Bladder Symptoms on Ambulatory Older Patients. Moderated podium presentation to the Society for Urodynamics and Female Urology 2016 Winter Meeting. New Orleans Louisiana. Ng, D. B., Flores, N., Nair, K., Kristy, R., Chapnick, J., Gooch, K., & Schermer, C. (2016, February): In *Neurology and Urodynamics* (Vol. 35, pp. S38-S38).
51. Mark B Efron, **Nair, KV.**, Cliff Molife, Stuart Y Keller, Robert L Page, Jason Simeone, Brian Murphy, Beth L Nordstrom, Yajun Zhu, Patrick L McCollam, George W Vetrovec Clinical Outcomes Using Prasugrel or Ticagrelor Based On Physician Treatment Decisions In Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: Comparative Results Using Propensity Analysis Of A Payer Database. Poster presentation at the Transcatheter Cardiovascular Therapeutics (TCT) Annual Meeting, October 11-15, San Francisco, 2015. *J Am Coll Cardiol.* 2015;66(15\_S) doi:10.1016/j.jacc.2015.08.184
52. Honce, J. M., **Nair, K. V.**, Sillau, S., Miravalle, A., Vollmer, B., Vollmer, T et al., Alvarez, E. Evaluating the relationship between brain volume and patient reported outcomes using clinical and imaging parameters collected in the routine care of MS patients. Poster at the 2015 American Academy of Neurology Meeting. April 18-25, 2015 Washington. *In Multiple Sclerosis Journal; Vol 21; 678-679*
53. Vollmer, B; Siebert, J; Sillau, S; Dowdle, P; Corboy, J, Vollmer, T; **Nair, KV**, Alvarez, EA. Comparison of Fingolimod and Dimethyl Fumarate in the Treatment of Multiple Sclerosis: One Year experience. Poster at the 2015 American Academy of Neurology Meeting. April 18-25, Washington, DC. In *Multiple Sclerosis Journal* (Vol. 21, pp. 536-536). In *Multiple Sclerosis Journal* (Vol. 21, pp. 536-536).
54. Alvarez, EA; Vollmer, B; Blackburn, J; Corboy, J, Vollmer, T; Silau, S, **Nair, KV**, Siebert, J. Effectiveness of Switching to Rituximab over Fingolimod or Dimethyl Fumarate after Natalizumab in Preventing Disease Activity in Multiple Sclerosis. Poster at the 2015 American Academy of Neurology Meeting. April 18-25, Washington, DC. In *Multiple Sclerosis Journal* (Vol. 21, pp. 544-544).
55. **Nair, KV**; Foley, J; Stephenson., Niecko, T., Agarwal, S., Watson, C., Physical aspects of quality of life over 3 years in patients with Multiple Sclerosis (MS) initiating natalizumab treatment earlier versus later in the course of disease. Poster at the 2015 American Academy of Neurology Meeting. April 18-25, Washington, DC. *Neurology April 6, 2015 vol. 84 no. 14 Supplement P3.276*
56. Watson, C. Foley, JF; **Nair, KV.**, Stephenson.J., Niecko, T., Agarwal, S., Treatment satisfaction over time for United States (US) patients with multiple sclerosis (MS) treated

- with natalizumab. Poster at the 2015 American Academy of Neurology Meeting. April 18-25, Washington, DC. *Neurology April 6, 2015 vol. 84 no. 14 Supplement P3.238*
57. McQueen, RB., Livingston, T., Vollmer, TL., Corboy, JH., **Nair, KV.**, Campbell, JD. Decreased Relapse Activity for those who Switch to Natalizumab from Alternative Disease Modifying Therapies: An Observational Study (P3.272) Poster at the 2015 American Academy of Neurology Meeting. April 18-25, Washington, DC. *Neurology April 6, 2015 vol. 84 no. 14 Supplement P3.272*
  58. Trinkley, K, Anderson, H, **Nair, KV.**, Malone, D, Saseen JJ. Defining the incidence of lactic acidosis in patients prescribed metformin with and without risk factors for lactic acidosis". Abstract submitted to the 2015 Society of General Internal Medicine Annual Meeting (accepted).
  59. Langness, J., Tabano, D., Tise, S., Pratt, L., Ayres, L., Wieland, A, Lin A, Ghushchyan V, **Nair, KV**, Everson, G. Simeprevir/Sofosbuvir vs Triple Therapy (Telaprevir or Boceprevir) for HCV GT1: A cost analysis," poster presentation at CROI (Conference on Retroviruses and Opportunistic Infections) 2015, Washington State Convention Center, in Seattle, Washington, USA, February 23-26, 2015.
  60. Warner. AW, **Nair, KV.** Estimating the Disease Burden of Hepatitis C in Colorado. Annual Meeting of the Council of State & Territorial Epidemiologists, Boston, 2015
  61. Kiser, Ty, Allen RR, **Nair, KV**, Vandivier, B. Impact of macrolide antibiotics on outcomes in ICU patients with acute exacerbations of COPD Abstract ID. 44th Critical Care Congress, January 17<sup>th</sup>-21<sup>st</sup>, 2015 Phoenix, Arizona. In *Critical Care Medicine*; Volume 42(12) Supplement 1, December 2014, p A1388
  62. Robert L Page II, Vahram Ghushchyan, Richard R Allen, Cynthia L Hartsfield, Bruce R Koch II, Gilead Sciences, **Nair, KV (senior author)**, Ranolazine Improves Diabetes and Cardiovascular Healthcare Utilization in Patients with Chronic Stable Angina and Diabetes. Poster presentation at the American Heart Association Annual Scientific Session Meeting, November 15-19, Chicago, IL. In *Circulation. November 25, 2014, Volume 130, Issue Suppl 2*
  63. Rhianna Tuchscherer, Ghushchyan, V, Allen RR, **Nair KV**, Sassen, JJ. PharmD Simvastatin and CCBs: A Comparison of Prescribing Practices before and after the U.S. FDA Updates to the 2011 Simvastatin Dosing Standards. Poster session at the 2014 National Lipid Association Annual Scientific Sessions, May 1 – 4, Orlando, Florida. In *Journal of Clinical Lipidology. May–June, 2014 Volume 8, Issue 3, Page 334*
  64. Wilson, Lisa, Ghushchyan, V, Allen RR, **Nair KV**, Sassen, JJ Comparison Of New-Onset Gout Incidence In Adults Prescribed Hydrochlorothiazide Versus Chlorthalidone. Poster session at the 29<sup>th</sup> American Society of Hypertension, Inc. (ASH) May 16 – 20, 2014, New York, New York. In *Journal of the American Society of Hypertension. April 2014*, Volume 8, Issue 4, Supplement, Page e28
  65. Page RL, Ghushchyan V, Hoetzer G, Bhandary D, Van Den Bos J, Grey T, Norris DT, **Nair KV (Senior)**. Death is expensive: Evaluation of inpatient mortality for acute coronary syndrome admission. American Heart Association, Poster Presentation at the American Heart Association Quality of Care and Outcomes Research (QCOR) Scientific Sessions. Baltimore, MD, June 2014. In *Circulation: Cardiovascular Quality and Outcomes. 2014; 7: A250*
  66. Page RL, Ghushchyan V, Allen RR, Hartsfield C, Koch BR, **Nair KV (Senior Author)**. Ranolazine improves cardiovascular outcomes and healthcare utilization: A comparative effective analysis with traditional antianginal agents. Poster Presentation at the American

- Heart Association-QCOR Scientific Sessions. Baltimore, MD, June 2014. In *Circulation: Cardiovascular Quality and Outcomes*. 2014; 7: A131
67. McQueen RB, Buckley B, Livingston T, Vollmer T, Corboy J, **Nair KV**, Campbell JD. Changes in Natalizumab Treatment Patterns and Association with Relapse Outcomes: A Retrospective Study. Poster presentation at the American Academy of Neurology 66th Annual Meeting, April 26 - May 3, 2014, Pennsylvania, Philadelphia, PA. In *Neurology April 8, 2014 vol. 82 no. 10 Supplement P7.227*
  68. Foley J, **Nair KV**, Stephenson JJ, Vollmer T, Niecko T, Agarwal S, Watson C, Patient-reported psychological functioning in natalizumab-treated patients with multiple sclerosis in US clinical practice. Poster presentation at the American Academy of Neurology 66th Annual Meeting, April 26 - May 3, 2014, Pennsylvania, Philadelphia, PA. In *Neurology April 8, 2014 vol. 82 no. 10 Supplement P4.183*
  69. Vollmer T, Foley J, **Nair KV**, Stephenson JJ, Niecko T, Agarwal S, Watson C. Impact of natalizumab treatment for multiple sclerosis on patient-reported physical functioning over 3 years in US clinical practices. Poster presentation at the American Academy of Neurology 66th Annual Meeting, April 26 - May 3, 2014, Pennsylvania, Philadelphia, PA. *Neurology April 8, 2014 vol. 82 no. 10 Supplement P7.210*
  70. Campbell JD, McQueen RB, Buckley B, Livingston T, Vollmer T, Corboy J, **Nair KV**. Retrospective Real-World Four-Year Study of Natalizumab Initiators: Persistence versus Non-Persistence Impact on Relapses and Associated Costs " Poster presentation at AMCP's 26th Annual Meeting & Expo in Tampa, Florida April 1-4, 2014
  71. McQueen RB, Buckley B, Livingston T, Vollmer T, Corboy J, **Nair KV**, Campbell J. Change in Natalizumab Real-World Treatment Patterns and Association with Relapse Outcomes: A Retrospective Study" Poster during AMCP's 26th Annual Meeting & Expo in Tampa, Florida April 1-4, 2014. In *Neurology April 8, 2014 vol. 82 no. 10 Supplement P7.227*
  72. McQueen RB, **Nair KV**, Vollmer TL, Campbell JD. Aggressive natalizumab treatment for JC Virus negative relapsing remitting MS. Cost effectiveness of first line versus second line natalizumab treatment. Poster presentation at ISPOR 19th Annual International Meeting to May 31 - June 4, 2014, Montreal, QC, Canada. In *Value and Health May 2014 Volume 17, Issue 3, Page A59*
  73. Page RL, Ghushchyan V, Gifford B, Allen RR, Raut M, Crivera C, Naim, AB, **Nair KV**. Atrial fibrillation and heart failure increase length of hospital stay, total healthcare utilization, and costs of acute coronary syndrome. American Heart Association Scientific Sessions. Dallas, TX. November 2013. In *Circulation November 2013, Volume 128, Issue Suppl 22*
  74. Ghushchyan V, Page RL, Gifford B, Allen RR, Raut M, Crivera C, Naim, AB, **Nair KV**. Economic burden of acute coronary syndrome: health care and productivity costs. International Society of Pharmaceutical Outcomes and Research. New Orleans, LA. May 2013. In *Value and Health. May 2013, Volume 16, Issue 3, Page A282*
  75. Page RL, Ghushchyan V, Gifford B, Allen RR, Raut M, Crivera C, Naim, AB, **Nair KV**. Economic Burden of Deep Vein Thrombosis and Pulmonary Embolism for Employees and Employers American Heart Association-QCOR Scientific Sessions. Baltimore, MD. May 2013. In *Circulation: Cardiovascular Quality and Outcomes*. 2013; 6: A229
  76. McQueen RB, Ellis SL, Maahs DM, Anderson HD, Libby AM, **Nair KV**, Garg SK, Campbell JD. Effectiveness of Continuous Glucose Monitoring for Type 1 Diabetes in Clinical Practice

- [abstract]. American Diabetes Association 73rd scientific sessions. June 21 – 25, 2013. *In Diabetes Vol. 62, pp. A228-A228*).
77. Ellis,SL, McQueen RB, Maahs DM, **Nair KV**, Anderson HD, Libby AM, Campbell JD. Glucose Differences in Patients with Type 1 Diabetes Who Continue versus Discontinue CGM Use [abstract]. American Diabetes Association 73rd scientific sessions. June 21 – 25, 2013. *In Diabetes; Vol. 62, pp. A218-A218*
  78. McQueen RB, Ellis SL, Maahs DM, Anderson HD, Libby AM, **Nair KV**, Campbell JD. Association of Blood Glucose Control with Health-Related Quality-of-life Utility for Type 1 Diabetes Pharmacoeconomic Models. *Value in Health* 2013. May; 16(3): Presented at the ISPOR 18th Annual International Meeting. May 18 – 22, 2013. [Selected as Finalist for Best Poster Presentation]. *In Value and Health. May 2013. May 2013, Volume 16, Issue 3, Page A169*
  79. Campbell JD, Ghushchyan VH, McQueen RB, Cahoon-Metzger S, Livingston TP, **Nair KV**. Generic quality of life burden of multiple sclerosis as compared to other debilitating chronic conditions. *Value in Health* 2013. May; 16(3): Presented at the ISPOR 18th Annual International Meeting. May 18 – 22, 2013. *In Value and Health. May 2013, Volume 16, Issue 3, Page A106*
  80. Padula WV, Makic MB, Mishra MK, Campbell JD, **Nair KV**, Wald HM, Valuck RJ. Comparative Effectiveness of Quality Improvement Interventions for Pressure Ulcer Prevention in US Hospitals. Society of Medical Decision Making, 35th Annual Meeting. October 20, 2013, Baltimore, MD.
  81. Padula WV, Mishra MK, Makic MBF, **Nair KV**, Campbell JD, Wald H, Valuck RJ. Implementation of Quality Improvement Interventions for Pressure Ulcer Prevention in University Health System Consortium Hospitals. ISPOR International Congress; May 2013, New Orleans, LA.
  82. Campbell, JD, Ghushchyan V, McQueen, RB, Metzger SC., Livingston, TP., Vollmer, T., Corboy, J., Mirvalle, A., Schreiner, **Nair, KV (senior author)**. Direct Costs, Indirect Costs, and Quality of Life Burden of Multiple Sclerosis: National US Estimates” Poster presentation at the American Academy of Neurology 65th Annual Meeting, March 16 -23, 2013 San Diego, CA. *In Neurology February 12, 2013 vol. 80 no. 7 Supplement P03.201*
  83. Vahram Ghushchyan, PhD; Robert Lee Page II.; Brian Gifford, Richard Allen;Ahmad B Naim; Monika Raut; Concetta Crivera, CV Damaraju,, **Nair, KV (senior author)**. The economic burden of acute coronary syndrome: healthcare and productivity costs. Poster presentation at the ISPOR 18th Annual International Meeting May 18-22, 2013, New Orleans, LA
  84. Sassen JJ., Tamas, FF., Allen, RR., McQueen, RB., **Nair, KV**,. Assessment of Blood Pressure Control in Patients at Goal on Olmesartan Monotherapy After Switching to either Irbesartan, Losartan or Valsartan. Poster presentation at the American Society of Hypertension (ASH) Twenty-Eighth Annual Scientific Meeting and Exposition, May 15 – 18, 2013. San Francisco, California.
  85. McQueen RB, Ellis SL, Maahs DM, Anderson HD, Libby AM, **Nair KV**, Campbell JD. Association of Blood Glucose Control with Health-Related Quality-of-Life Utility for Type 1 Diabetes Pharmacoeconomic Models. Poster presentation at the ISPOR 18th Annual International Meeting May 18-22, 2013 at the Sheraton New Orleans in New Orleans, LA, USA

86. William V Padula, Mary Beth F Makic, Manish K Mishra, Heidi M Wald, **Nair, KV**, Jonathan D Campbell, Robert J Valuck, Implementation of quality improvement interventions for pressure ulcer prevention in university healthsystem consortium hospitals. Poster presentation at the ISPOR 18th Annual International Meeting May 18-22, 2013, New Orleans, LA, USA.
87. Lofland, J., Vanderpoel, J, Nair, KV., Crohn's Disease Patients with Early Biologic Treatment Versus Late Biologic Treatment: Comparison of Patient Response to Therapy and Healthcare Costs. In *Inflammatory Bowel Disease*, [December 2013](#), Vol 19; Suppl
- 
88. **Nair, KV**, Vahram Ghushchyan, Lisa A Thompson, Cindy L. O'Bryant, Richard Read Allen, Robert Brett McQueen. Examining the impact of frequent versus infrequent screenings for breast cancer on employer costs. American Society of Clinical Oncology (ASCO) Annual Meeting. June 1 – 5, 2012.
89. Padula WV, Makic MBF, Mishra MK, **Nair KV**, Campbell JD, Wald H, Valuck RJ. An off-the-shelf catalogue of quality improvement interventions to implement in the prevention of pressure ulcers for hospital settings. ISPOR European Congress; November 2012, Berlin, Germany.
90. Page RL II, Ghushchyan V, Gifford B, Allen RR, Raut M, Crivera C, Naim AB, **Nair KV (senior author)**. Economic burden of acute coronary syndrome for employees and their dependents: Medical and productivity costs. American Heart Association Scientific Sessions. Los Angeles, CA. November 2012.
91. Padula WV, Makic MBF, Mishra MK, **Nair KV**, Campbell JD, Wald H, Valuck RJ. An off-the-shelf catalogue of quality improvement interventions to implement in the prevention of pressure ulcers for hospital settings. ISPOR European Congress; November 2012, Berlin, Germany.
92. Trinkley, A., Moore, G., Smith S, **Nair, KV (senior author)**. A reimbursement model through a University's self-insurance for ambulatory care clinical pharmacy services. ", Poster presentation at the ACCP's Annual Meeting, October 23, 2012. The ACCP Annual Meeting Hollywood, Florida
93. **Nair, KV**, Ghushchyan, V, Thompson, LA, O'Bryant, CL, Allen, RR, McQueen, RM. J. Examining the impact of frequent versus infrequent screenings for breast cancer on employer costs. *Clin Oncol* 30, 2012 (suppl; abstr e16550).
94. Thompson, LA, Saseen, JJ, O'Bryant, C, Allen, RR, **Nair, KV (senior author)** Estimation of hypertension (HTN) occurrence, severity changes, and patterns of antihypertensive (AH) use in patients receiving VEGF inhibitors for the treatment of cancer. *J Clin Oncol* 30, 2012 (suppl; abstr e16541).
95. **Nair KV**, Ghushchyan V, Allen R, Prasala K, McQueen RB, Puyear M, Stolshek B Association Between Adherence to Oral Bisphosphonate Osteoporosis Medications, Fracture Rates, and Expenditures. *Journal of Managed Care Pharmacy*. Vol. 18, No. 2 March 2012, pp 161.
96. Campbell, J, McQueen, RB, **Nair, KV**, Vollmer, T. Corboy, J., New Versus Old: Long-Term Comparative Effectiveness Research Projections for Disease Modifying Therapies in Relapse-Remitting Multiple Sclerosis. Poster presentation at the American Academy of Neurology 64th Annual Meeting, April 21 to April 28, 2012, New Orleans, LA.
97. **Nair KV.**, Ghushchyan V, Allen R, McQueen R, Robinson T, Hargreaves J. Patient Demographics and surgical expenditures in hernia repair surgical cohorts using a retrospective nationwide patient database. Poster presentation at the International Society



- for Pharmacoeconomics and Outcomes Research 14<sup>th</sup> Annual European Congress Meeting. November 5-8<sup>th</sup>, 2011 Madrid Spain
98. Saseen, JJ., Agashivala, N., Allen, RR., Ghushchyan, V, **Nair, KV**. Frequency of gouty arthritis attacks and presence of comorbid conditions have an impact on gout-related healthcare resource utilization and costs. Poster presentation at the 2011 ACR/ARHP Annual Scientific Meeting, to be held in Chicago, IL, November 4 -9, 2011.
  99. Hanselin, MR., Saseen, JJ., Allen, RR., Maars, JC., **Nair, KV**. Description of antihypertensive use in patients with resistant hypertension prescribed four or more agents. Poster presentation at the 2011 American Colleges of Clinical Pharmacy Annual Meeting. October 16-19<sup>th</sup>, Pittsburgh, PA.
  100. Alford, JC., Saseen, JJ., Allen, RR., **Nair, KV** Persistent use of against label statin-fibrate combinations from 2003 to 2009 despite FDA dose restrictions. Poster presentation at the 2011 American Colleges of Clinical Pharmacy Annual Meeting. October 16-19<sup>th</sup>, Pittsburgh, PA.
  101. Bagley, C., Ghushchyan, **Nair, KV (senior author)**. To estimate changes in prescription utilization and associated costs in 2014 after the implementation of the Patient Protection and Affordable Act. Poster presentation at the Western Pharmacoeconomics Conference (WPC), 2011 March 31-April 2, Seattle, WA.
  102. Ahmad, N., **Nair, KV (senior author)**., Fortner, G., Digenarro, A., Managing Health-risk, Health Status and Productivity in Chronic Kidney Disease: An Innovative Chronic Care Management Solution for Employers. Presentation at the American Occupational Health Conference March 24-25<sup>th</sup>, 2011, Washington, DC
  103. Ghushchyan VH, Sullivan PW, Naim A, **Nair KV (senior author)**. Expected changes in healthcare utilization due the Patient Protection and the Affordable Care Act. Poster presentation at the International Society for Pharmacoeconomics and Outcomes Research 16<sup>th</sup> Annual Meeting. May 21-25, 2011 Baltimore, MD.
  104. Padula, W **Nair KV (senior author)**. The cost of obesity and major comorbidities: Analysis from a commercial claims database. Poster presentation at the International Society for Pharmacoeconomics and Outcomes Research 16<sup>th</sup> Annual Meeting. May 21-25, 2011 Baltimore, MD.
  105. Slejko, J., Campbell, **Nair KV** et al., New statin users persistence and adherence: Both are critical concepts in comprehensive characterization of medication exposure., Poster presentation at the International Society for Pharmacoeconomics and Outcomes Research 16<sup>th</sup> Annual Meeting. May 21-25, 2011 Baltimore, MD.
  106. Naim, A., **Nair KV (senior author)**, Harshman, R et al., Early detection, screening and management of chronic kidney disease among the actively employed: An integrated approach to population health management. Poster presentation at the International Society for Pharmacoeconomics and Outcomes Research 16<sup>th</sup> Annual Meeting. May 21-25, 2011 Baltimore, MD
  107. Abott, Z., Allen, RR., **Nair, KV.**, Akuthota, V., Utilization Characteristics of Spinal Interventions (2011 Outstanding Paper Award for Medical & Interventional Science) The Spine Journal, Volume 10, Issue 9, Supplement , Page S68, September 2010.
  108. **Nair, KV.**, Jan, S., Belletti, D., Doyle, J., Allen, RR., Patel, JV., Understanding barriers to medical adherence for medication adherence. International Society for

- Pharmacoeconomics and Outcomes Research 15<sup>th</sup> Annual Meeting, May 15-19, 2010 Atlanta Georgia.
109. Naim A., **Nair, KV (senior author)**., Vandebos, J., Comparison of absenteeism and total healthcare expenditures for select autoimmune inflammatory disorders pre and post anti TNF use: An employers perspective. International Society for Pharmacoeconomics and Outcomes Research 15<sup>th</sup> Annual Meeting, May 15-19, 2010 Atlanta Georgia.
  110. Naim A., **Nair, KV (senior author)**., Vandebos, J., Comparison of absenteeism and total healthcare expenditures for inflammatory bowel disease pre and post anti TNF use: An employers perspective. International Society for Pharmacoeconomics and Outcomes Research 15<sup>th</sup> Annual Meeting, May 15-19, 2010 Atlanta Georgia.
  111. **Nair, KV.**, Corboy, J., Patel, NM., Kahler, K., Bainbridge, J., McQueen, RB., Ghushchyan, V., Allen, RR., Diagnostic Tests and Procedures for Treated and Untreated Patients with Multiple Sclerosis (MS). Poster presentation at the American Academy of Neurology 62nd Annual Meeting, April 10 to April 17, 2010 at the Metro Toronto Convention Centre in Toronto, Ontario, Canada
  112. Abbott, Z., **Nair, KV.**, Allen, RR., Akhuthota, V. Utilization Characteristics of Spinal Interventions. Poster presentation at the North American Spine Society 2010 25<sup>th</sup> Annual Meeting, October 5-9th in Orlando, FL.
  113. **Nair, KV.**, Patel, NM., Corboy, J., Bainbridge, J., Saseen J., Allen, RR., Evaluating patterns of monitoring in Multiple Sclerosis through a retrospective database analysis. Poster S72. Presented at the 23<sup>rd</sup> Annual Meeting of the Consortium for Multiple Sclerosis, May 27-30<sup>th</sup>, Atlanta, GA, 2009.
  114. Naim, A., **Nair, KV (senior author)**., Vandebos, J., Tang, B., Rustagi, K., Piech, C. Comparison of Total Health Care Expenditures and Absenteeism for Select Autoimmune Inflammatory Disorders From an Employer's Perspective. Poster PRR-24: Presented at the Academy of Managed Care 2009 Educational Meeting, Oct 7-9, San Antonio, Texas
  115. **Nair, KV.**, Naim, A., Vandebos, J., Tang, B., Rustagi, K., Piech, C., Comparison of Total Healthcare Expenditures and Absenteeism for Select Auto-immune Inflammatory Disorders (AIID) from an Employer's Perspective (**abstract # 693801**)." To be presented at the American Occupational Health Conference, to be held May 2-5, 2010 in Orlando, Florida.
  116. **Nair KV**, Tang B, Van Den Bos J, Zhang V, Saseen J, Rahman M. A Five-Year Longitudinal Analysis Comparing Dose Changes for Patients With Rheumatoid Arthritis Taking Infliximab in a Medicare and in a Commercially Insured Population. 71<sup>st</sup> Annual Meeting of the American College of Rheumatology. Boston, MA, November 2007.
  117. **Nair KV**, Tang B, Van Den Bos J, Zhang V, Naim A, Rahman M. Comparing Medical Utilization and Expenditures Between Switchers and Non Switchers for Tumor Necrosis Factor Inhibitors (Anti-TNFs) in the Treatment of Rheumatoid Arthritis. 71<sup>st</sup> Annual Meeting of the American College of Rheumatology. Boston, MA, November 2007.
  118. **Nair KV**, Tang B, Van Den Bos J, Zhang V, Naim A, Rahman M. Association Between Dose Changes and Healthcare Costs in Rheumatoid Arthritis Patients Who Received Infliximab Therapy. International Society for Pharmacoeconomics and Outcomes Research 10<sup>th</sup> Annual European Congress. Dublin, Ireland, October 2007.
  119. **Nair KV**, Tang B, Van Den Bos J, Zhang V, Saseen J, Rahman M. A Five-Year Longitudinal Analysis Comparing Dose Changes for Patients with Rheumatoid Arthritis

- Taking Infliximab in a Medicare and in a Commercially Insured Population. International Society for Pharmacoeconomics and Outcomes Research 1<sup>st</sup> Latin America Conference. Cartagena, Colombia, September 2007.
120. **Nair KV**, Tang B, Van Den Bos J, Zhang V, Saseen J, Rahman M. A Five-Year Longitudinal Analysis Comparing Dose Changes for Patients With Rheumatoid Arthritis Taking Infliximab in a Medicare and in a Commercially Insured Population. International Society for Pharmacoeconomics and Outcomes Research 12<sup>th</sup> Annual International Meeting. Arlington, VA, May 2007. *Value in Health* May/June 2007; 10(3):A122 (abstract PAR15).
  121. **Nair KV**, Park, J, Saseen J, Wolfe, PW, Saseen JJ, Allen RR., Health Reimbursement Account Based Consumer Driven Health Plans: Their Impact on Medical Utilization, Pharmacy Utilization and Expenditures. International Society for Pharmacoeconomics and Outcomes Research 12<sup>th</sup> Annual International Meeting. Arlington, VA, May 2007. *Value in Health* May/June 2007; 10(3):A28
  122. **Nair, KV**. Valuck, RJ. Impact of increased copayments on the switching and discontinuation rates for non formulary medications. Poster presentation at the 10<sup>th</sup> Annual *International Meeting of the International Society on Pharmacoeconomic and Outcomes Research*, May 15-18, 2005; Arlington, VA. (Abstract featured in *Value and Health* May/June 2005, Volume 8, Number 3; pp 283).
  123. **Nair, KV**. Sullivan. PW. Patient perceptions regarding the use of OTC Claritin. Poster presentation at the 10<sup>th</sup> Annual International Meeting of the International Society on Pharmacoeconomic and Outcomes Research, May 15-18, 2005; Arlington, VA. (Abstract featured in *Value and Health* May/June 2005, Volume 8, Number 3; pp 339).
  124. Sullivan. PW, **Nair, KV**, Patel, BV. The impact of the Rx to OTC switch of loratadine and changes in prescription drug benefits on utilization and cost of drug therapy. Poster presentation at the 10<sup>th</sup> Annual International Meeting of the International Society on Pharmacoeconomic and Outcomes Research, May 15-18, 2005; Arlington, VA. (Abstract featured in *Value and Health* May/June 2005, Volume 8, Number 3; pp 338).
  125. **Nair, KV**. Valuck, RJ. Allen, RR. Rates of continuation of non formulary medications for chronic disease sufferers in multi-tiered pharmacy benefit plans. Poster presentation at the 8<sup>th</sup> Annual International Meeting of the International Society on Pharmacoeconomic and Outcomes Research, May 18-21, 2003; Arlington, VA. (Abstract featured in *Value and Health* May/June 2003, Volume 6, Number 3; pp 209).
  126. **Nair KV**, Ganther, JM., Valuck, RJ. , McCollum, M., Lewis, SJ., Impact of multi-tiered pharmacy benefits on patient attitudes regarding formulary and non formulary medications, (Poster presentation) at the Annual Meeting of the Academy of Managed Care Pharmacy, Salt Lake City UT, April, 2002. (Abstract featured in *Journal of Managed Care Pharmacy* March/April 2002, Volume 8, Number 2; pp 116,117).
  127. Valuck, RJ Williams, SA ; MacArthur, M ; Saseen, JJ ; **Nair, K** et al., Patters of hyperlipidemia pharmacological treatment in managed care organizations. (Poster presentation) at the 37<sup>th</sup> Midyear Clinical Meeting of the American Society of Health-System Pharmacists, December, 2002, Atlanta, GA.
  128. Valuck, RJ Williams, SA ; MacArthur, M ; Saseen, JJ ; **Nair, K** et al., Determinants of Successful Outcome in Hyperlipidemia Management. Poster presentation at the 4th Scientific Forum on Quality of Care and Outcomes Research in Cardiovascular Disease and

- Stroke of the American Heart Association, October, 2002, Washington, DC. (Abstract featured in *Circulation*, Volume 106, Number 16; pp 20-21).
129. M McCollum, RL Page, **KV Nair**, RJ Valuck. Gender bias in the use of beta-blocker therapy in heart failure patients: report from the GRACE study. *PHARMACOTHERAPY* 23 (3), 414-414
130. **Nair, KV.**, Ganther, JM. Valuck, RJ. McCollum, M. Evaluating patient attitudes related to multi-tiered pharmacy benefits. San Francisco, March, 2001. (Abstract featured in *Journal of the American Pharmaceutical Association*. March/April 2001, Volume 41, Number 2; pp 138).
131. **Nair, KV.**, Improving the performance of P&T Committees. American Pharmaceutical Association's National Meeting, Washington DC, March, 2000. (Abstract featured in *Journal of the American Pharmaceutical Association*. March/April 2000, Volume 40, Number 2, pp 323).
132. Follin, S, Page, R, **Nair, KV**. Evaluation of patient perceptions and acceptance of clinical pharmacy services in an urban community pharmacy setting. American-Society of Health Systems Pharmacists Mid-Year Clinical Meeting. Las Vegas, Nevada, Dec, 2000. (Abstract featured in the 34<sup>th</sup> ASHP Midyear Clinical Meeting Abstracts, 35(Dec): p P-73E. 2000).
133. **Nair, KV.**, Ascione, FJ.,. Improving the Performance of Pharmacy and Therapeutic Committees. American Pharmaceutical Association's National Meeting, San Antonio, Texas, March, 1999. (Abstract featured in *Journal of the American Pharmaceutical Association*. March/April 1999, Volume 39, Number 2).
134. **Nair, KV.**, Ascione, FJ., Factors influencing performance of Pharmacy and Therapeutics Committees. American Pharmaceutical Association's National Meeting, Miami, Florida, March, 1998. (Abstract featured in *Journal of the American Pharmaceutical Association*. May/June 1998, Volume 38, Number 3).
135. Kirking, DM. Gaither, CA. **Nair, KV**. Knapp, BR. Knox, TL. Computer-based mastery examination for teaching principles of research. American Association of Colleges of Pharmacy Annual Meeting. 100(Jul): p 75. 1999.